

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Risk Factors and Clinical Outcomes of Functional Decline during Acute Decompensated Heart Failure Hospitalization: Observations from the KCHF Registry

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-032674
Article Type:	Research
Date Submitted by the Author:	03-Jul-2019
Complete List of Authors:	<p>Yaku, Hidenori; Kyoto University Graduate School of Medicine Faculty of Medicine, Department of Cardiovascular Medicine Kato, Takao; Kyoto University Graduate School of Medicine Faculty of Medicine, Department of Cardiovascular Medicine; Kyoto University Graduate School of Medicine Morimoto, Takeshi; Hyogo Collge of Medicine, Division of General Internal Medicine Inuzuka, Yasutaka; Shiga Medical Center for Adults, Cardiology Tamaki, Yodo; Public Interest Incorporated Foundation Tenri Hospital, Cardiology Ozasa, Neiko; Kyoto University Graduate School of Medicine Faculty of Medicine, Department of Cardiovascular Medicine Yamamoto, Erika; Kyoto University Graduate School of Medicine Faculty of Medicine, Department of Cardiovascular Medicine Yoshikawa, Yusuke; Kyoto University Graduate School of Medicine Faculty of Medicine, Department of Cardiovascular Medicine Kitai, Takeshi; Kobe City Medical Center General Hospital, Cardiology Kato, Masashi; Mitsubishi Kyoto Hospital, Department of Cardiology Ikeda, Tomoyuki; Hikone Municipal Hospital, Department of Cardiology Furukawa, Yutaka; Kobe City Medical Center General Hospital, Department of Cardiovascular Medicine Nakagawa, Yoshihisa; Shiga University Graduate School of Medicine Sato, Yukihiro; Hyogo Prefectural Amagasaki Hospital Kuwahara, Koichiro ; Shinshu University Graduate School of Medicine School of Medicine, Cardiovascular Medicine Kimura, Takeshi; Kyoto University Graduate School of Medicine Faculty of Medicine, Department of Cardiovascular Medicine</p>
Keywords:	Heart failure < CARDIOLOGY, Adult cardiology < CARDIOLOGY, Cardiac Epidemiology < CARDIOLOGY

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

Risk Factors and Clinical Outcomes of Functional Decline during Acute

Decompensated Heart Failure Hospitalization: Observations from the KCHF Registry

Authors: Hidenori Yaku, MD ^a, Takao Kato, MD ^a, Takeshi Morimoto, MD, MPH ^b, Yasutaka Inuzuka, MD ^c, Yodo Tamaki, MD ^d, Neiko Ozasa, MD ^a, Erika Yamamoto, MD ^a, Yusuke Yoshikawa, MD ^a, Takeshi Kitai, MD ^e, Masashi Kato, MD ^f, Tomoyuki Ikeda ^g, Yutaka Furukawa, MD ^e, Yoshihisa Nakagawa, MD ^h, Yukihito Sato, MD ⁱ, Koichiro Kuwahara, MD ^j, Takeshi Kimura, MD ^a, for the KCHF study investigators

Affiliations: ^a Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan; ^b Department of Clinical Epidemiology, Hyogo College of Medicine, Hyogo, Japan; ^c Department of Cardiovascular Medicine, Shiga General Hospital, Shiga, Japan; ^d Division of Cardiology, Tenri Hospital, Nara, Japan; ^e Department of Cardiovascular Medicine, Kobe City Medical Center General Hospital, Hyogo, Japan; ^f Department of Cardiology, Mitsubishi Kyoto Hospital, Kyoto, Japan; ^g Department of Cardiology, Hikone Municipal Hospital, Shiga, Japan; ^h Department of Cardiovascular Medicine, Shiga University Graduate School of Medicine, Shiga, Japan; ⁱ Department of Cardiology, Hyogo Prefectural Amagasaki General Medical Center, Hyogo, Japan; ^j Department of Cardiovascular Medicine, Shinshu University Graduate School of Medicine,

1
2
3
4 Nagano, Japan.
5
6
7

8
9 **Corresponding Author:** Takao Kato, MD.

10 Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine

11
12
13 54 Shogoin Kawahara-cho, Sakyo-ku, Kyoto. 606-8507 Japan
14

15
16
17 Tel: +81-75-751-4254; FAX: +81-75-751-3289; E-mail: tkato75@kuhp.kyoto-u.ac.jp
18
19

20
21
22 **Manuscript word count:** 2793 words
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Abstract

Objective: To investigate the prevalence and risk factors of functional decline during hospitalization, and its relationship with post-discharge outcomes in patients with acute decompensated heart failure (ADHF) hospitalization.

Design: Prospective cohort study between October 1, 2014, and March 31, 2016.

Setting: A physician-initiated multicentre study of consecutive patients admitted for ADHF into 1 of 19 secondary and tertiary hospitals throughout Japan.

Participants: Among 3555 patients hospitalized for ADHF (median age [IQR], 80 [71-86] years; 1572 [44%] women), functional decline during the index hospitalization occurred in 528 patients (15%).

Primary and secondary outcomes: The primary outcome measure was a composite of all-cause death or heart failure hospitalization after discharge. The secondary outcome measures were all-cause death and heart failure hospitalization.

Results: The independent risk factors for functional decline included age ≥ 80 years (OR 2.56; 95% CI 1.98–3.32), women (OR 1.27; 95% CI 1.01–1.60), prior stroke (OR 1.61; 95% CI 1.23–2.10), dementia (OR 1.95; 95% CI 1.52–2.52), elevated body temperature (OR 1.88; 95% CI 1.29–2.74), hyponatremia (OR 1.46; 95% CI 1.07–1.98), decreased albumin levels

1
2
3
4 (OR 1.69; 95% CI 1.27–2.24), renal dysfunction (OR 1.54; 95% CI 1.21–1.96), and New
5
6
7 York Heart Association class III/IV on admission (OR 1.51; 95% CI 1.05–2.18) after
8
9
10 multivariable adjustment. The cumulative 1-year incidence of the primary outcome in the
11
12
13 functional decline group was significantly higher than that in the no functional decline group
14
15
16
17 (50% vs. 31%, log-rank $P < 0.001$). After adjusting for baseline characteristics, the higher risk
18
19
20 of the functional decline group relative to the no functional decline group remained
21
22
23
24 significant (adjusted HR 1.50; 95% CI 1.29–1.75; $P < 0.001$).

25
26
27 **Conclusions:** Independent risk factors of functional decline in ADHF patients were related to
28
29
30 both frailty and severity of heart failure. Functional decline during hospitalization was
31
32
33 associated with unfavourable post-discharge outcomes.
34
35

36
37 **Trial Registration:** <https://clinicaltrials.gov/ct2/show/NCT02334891> (NCT02334891) and
38
39
40 https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000017241
41
42
43
44 (UMIN000015238)
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Strengths and limitations of this study

- This study is the first large-scale contemporary multicentre study reporting the prevalence of functional decline in patients hospitalized for acute decompensated heart failure (ADHF).
- Functional decline during hospitalization occurred in 15% of patients, and 80% of those with functional decline were ambulatory before admission
- The severity of symptoms or patient status specific for heart failure was associated with functional decline independent of well-known factors in acute medical illness.
- Functional decline during ADHF hospitalization was statistically significantly associated with a higher risk for the primary composite outcome of mortality or heart failure readmission.
- We did not collect data regarding on-site and outpatient rehabilitation and nutritional support.

Introduction

Functional decline in hospitalized patients is a complex and dynamic process [1–3]. Functional decline during hospitalization was reported to occur in approximately 30-50% of patients hospitalized for acute medical illness [2,4,5]. In the rapidly aging societies, the number of patients hospitalized for acute decompensated heart failure (ADHF) is increasing, and ADHF has become the leading cause of hospitalization due to acute medical illness. In older patients, functional decline associated with hospitalization often leads to subsequent inability to live actively and independently.

However, there is a scarcity of data regarding the risk factors of functional decline in patients hospitalized for ADHF. Identifying high-risk patients for functional decline during hospitalization would be useful for its prevention. Furthermore, no previous study focused on subsequent clinical outcomes in patients with functional decline during hospitalization.

Therefore, we sought to clarify the risk factors for functional decline during hospitalization in patients with ADHF and to compare the 1-year clinical outcomes between the 2 groups of patients with and without functional decline during the hospitalization for ADHF in a large Japanese observational database of hospitalized patients for ADHF in the real-world clinical practice.

Methods

Study Design, Setting, and Population

The Kyoto Congestive Heart Failure (KCHF) registry is a physician-initiated, prospective, observational, multicentre cohort study that enrolled consecutive patients who were hospitalized for ADHF for the first time between October 1, 2014, and March 31, 2016. These patients were admitted into 19 secondary and tertiary hospitals, including rural and urban as well as large and small institutions, throughout Japan. The study protocol was approved by the institutional review board of each participating hospital. A waiver of written informed consent from each patient was granted by the institutional review boards of Kyoto University and each participating centre because the study met the conditions of the Japanese ethical guidelines for epidemiological study and the US policy for protecting human research participants.[6,7] This study followed the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting guideline.

The details of the KCHF study design and patient enrolment are described elsewhere.[8,9] Briefly, we enrolled all patients with ADHF, as defined by the modified Framingham criteria, who were admitted to the participating hospitals and patients who underwent heart failure-specific treatment involving intravenous drugs within 24 hours after

1
2
3
4 hospital presentation. Patient records were anonymized before analysis. Data analysis was
5
6
7
8 conducted from August 2018 to October 2018.
9

10
11 Among 4056 patients enrolled in the KCHF registry, 3785 patients were discharged
12
13
14 alive after hospitalization for ADHF. Clinical follow-up data were collected in October 2017.

15
16
17 The attending physicians or research assistants at each participating hospital collected clinical
18
19
20
21 events after the index hospitalization from hospital charts or by contacting patients, their
22
23
24 relatives, or their referring physicians with consent. The present analysis had 2 objectives.

25
26
27 First, we sought to clarify the risk factors for functional decline during hospitalization of
28
29
30
31 ADHF patients. Second, we sought to compare the 1-year clinical outcomes between the 2
32
33
34 groups of patients with and without functional decline during the hospitalization for ADHF.
35

36
37 Among 4056 patients enrolled in the KCHF registry, the current study population consisted
38
39
40
41 of 3555 patients who were discharged alive and were assessed for functional decline during
42
43
44 hospitalization, excluding 271 patients who died during the index hospitalization, 99 patients
45
46
47 whose functional status before admission and/or at discharge was not available, and 131
48
49
50
51 patients who were bedridden before index hospitalization (Figure 1). The long-term
52
53
54 follow-up was censored at 1-year. The primary outcome measure in the current analysis was
55
56
57 a composite of all-cause death or heart failure hospitalization at 1-year. The secondary
58
59
60

1
2
3
4 outcome measures were all-cause death and heart failure hospitalization.
5
6

7 **Definitions**

8
9
10 Physical activity before admission and at discharge was classified by mobility
11
12 status based on the definition of Japanese long-term care insurance into ambulatory
13
14 (including those patients using any aid such as stick), use of wheelchair outdoor only, use of
15
16 wheelchair indoor and outdoor, and bedridden state [8]. Functional decline was defined as the
17
18 decline of at least one stage on physical activity at discharge compared with pre-admission
19
20 status. In-hospital worsening heart failure was defined as additional intravenous drug
21
22 administration for heart failure, haemodialysis, or mechanical circulatory or respiratory
23
24 support, occurring >24 hours after therapy initiation [10]. In-hospital worsening renal
25
26 function was defined as >0.3 mg/dL increase in serum creatinine levels during the index
27
28 hospitalization [11–13]. Detailed definitions of baseline clinical characteristics including the
29
30 signs and symptoms of heart failure were described previously [9].
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

47 **Statistical Analysis**

48
49
50 Categorical variables were presented as numbers with percentages and compared
51
52 using χ^2 test. Continuous variables were expressed as the mean with standard deviation or
53
54 median with 25th to 75th percentiles, and compared using the Student's *t* test when normally
55
56
57
58
59
60

1
2
3
4 distributed or Wilcoxon rank-sum test when not normally distributed.
5
6

7
8 We compared baseline characteristics and clinical outcomes based on the presence
9
10 or absence of functional decline during the index hospitalization. A multivariable logistic
11
12 regression model was developed to identify clinical characteristics associated with an
13
14 increased risk for functional decline. We used 23 clinically relevant factors listed in Table 1
15
16 as potential independent risk factors in the multivariable logistic regression model and
17
18 estimated the odd ratios (ORs) and 95% confidence intervals (CIs). We used the
19
20 Kaplan-Meier method to estimate the cumulative 1-year incidences of the outcome measures
21
22 and assessed the differences with the log-rank test. We expressed the associations of the
23
24 functional decline group with the no functional decline group for all outcome measures as
25
26 hazard ratios (HRs) with 95% CIs by multivariable Cox proportional hazard models
27
28 incorporating the 23 clinically relevant risk-adjusting variables indicated in Table 1. We also
29
30 conducted subgroup analyses stratified by age, sex, LVEF, anaemia, albumin levels, body
31
32 temperature, and the symptomatic status at discharge (oedema and general malaise at
33
34 discharge). In the multivariable analysis and subgroup analyses, continuous variables were
35
36 dichotomized by clinically meaningful reference values or median values; age ≥ 80 years
37
38 based on the median value, LVEF $< 40\%$ based on the heart failure guideline of LVEF
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 classification [14], BMI ≤ 22 kg/m², renal dysfunction (eGFR < 30 ml/min/1.73m²) based on
5
6
7
8 CKD grade, decreased albumin levels (serum albumin < 3.0 g/dL), hyponatremia (serum
9
10
11 sodium < 135 mEq/L), elevated body temperature (body temperature $\geq 37.5^{\circ}\text{C}$) based on the
12
13
14 cut-off value in metabolic syndrome [15].
15
16

17
18 We performed an additional analysis using the data including those patients who
19
20
21 died during the index hospitalization and those who were bedridden before the index
22
23
24 hospitalization, and evaluated the factors associated with functional decline or in-hospital
25
26
27 mortality by constructing multivariable adjusted Cox models. All statistical analyses were
28
29
30 conducted by a physician (H.Y.) and a statistician (T.M.) with JMP 13.0 or SAS 9.4 (both
31
32
33
34 SAS Institute Inc, Cary, NC). Two-tailed P-values less than 0.05 were considered statistically
35
36
37 significant.
38
39

40 41 **Patient and public involvement**

42
43
44 No patient involved.
45
46
47
48
49
50

51 **Results**

52 53 54 **Baseline Clinical Characteristics**

55
56
57 Among 3555 study patients, physical activity before admission included
58
59
60

1
2
3
4 ambulatory in 2949 patients (83%), wheelchair outdoor only in 272 patients (7.7%), and
5
6
7 wheelchair outdoor and indoor in 334 patients (9.4%). At hospital discharge, functional
8
9
10 decline was observed in 420 patients (14%) who were ambulatory before admission, in 80
11
12
13 patients (29%) who had used wheelchair outdoor only, and in 28 patients (8.4%) who had
14
15
16 used wheelchair outdoor and indoor. Consequently, decline in functional status was observed
17
18
19 in 528 patients (15%; functional decline group), while functional decline was not observed in
20
21
22 3027 patients (85%; no functional decline group) (eFigure 1). Wheelchair outdoor only
23
24
25 before admission were more prevalent in the functional decline group than in the no
26
27
28 functional decline group; however, 80% of patients in the functional decline group were
29
30
31 ambulatory before admission (Table 1).
32
33
34
35
36
37

38 Regarding the baseline clinical characteristics, the patients in the functional decline
39
40 group were older and had a higher prevalence of hypertension, prior stroke, renal
41
42 dysfunction, dementia, malignancy, anaemia, decreased albumin levels, and hyponatremia
43
44 (Table 1). There were no significant differences in previous heart failure hospitalization,
45
46
47 atrial fibrillation or flutter, previous myocardial infarction, chronic lung disease, and living
48
49
50 alone status as a social background between the 2 groups (Table 1). The functional decline
51
52
53 group was more likely to have a valvular aetiology, lower blood pressure, lower heart rate,
54
55
56
57
58
59
60

1
2
3
4 higher levels of brain natriuretic peptide (BNP) or N-terminal portion of proBNP
5
6
7 (NT-proBNP), and a higher LVEF (Table 1). The proportion of patients who achieved relief
8
9
10 of signs and symptoms on admission after the treatment in the emergency room was not
11
12
13 significantly different between the 2 groups (14% vs. 16%, P=0.25).
14
15
16

17 **Risk Factors for Functional Decline**

18
19
20 Among the baseline characteristics and status at hospital presentation, the following
21
22 independent risk factors for functional decline during hospitalization were identified by the
23
24 multivariable logistic regression analysis: age ≥ 80 years (OR 2.56; 95% CI 1.98–3.32),
25
26 women (OR 1.27; 95% CI 1.01–1.60), prior stroke (OR 1.61; 95% CI 1.23–2.10), dementia
27
28 (OR 1.95; 95% CI 1.52–2.52), body temperature $\geq 37.5^{\circ}\text{C}$ (OR 1.88; 95% CI 1.29–2.74),
29
30 hyponatremia (OR 1.46; 95% CI 1.07–1.98), decreased albumin levels (OR 1.69; 95% CI
31
32 1.27–2.24), eGFR < 30 ml/min/1.73m² (OR 1.54; 95% CI 1.21–1.96), and New York Heart
33
34 Association (NYHA) class III/IV on admission (OR 1.51; 95% CI 1.05–2.18) (Figure 2 and
35
36 eTable 1).
37
38
39
40
41
42
43
44
45
46
47
48
49

50 **In-hospital adverse events and status at discharge**

51
52 The median length of hospital stay was longer in the functional decline group than
53
54 in the no functional decline group (21 days vs. 15 days, P <0.001). Regarding the in-hospital
55
56
57
58
59
60

1
2
3
4 adverse events, the prevalence of worsening heart failure, worsening renal function, and
5
6
7 stroke was higher in the functional decline group than in the no functional decline group
8
9
10 (Table 2). The proportion of patients with symptoms such as dyspnoea on exertion, oedema,
11
12
13 general malaise, and loss of appetite at discharge was higher in the functional decline group
14
15
16 than in the no functional decline group (Table 2). Consequently, the proportion of patients in
17
18
19 the functional decline group discharged to home was also lower (47% vs. 90%, $P < 0.001$).
20
21
22
23
24 Regarding medical treatment at discharge, angiotensin-converting enzyme inhibitor or
25
26
27 angiotensin receptor blocker (ACEI/ARB), and beta blocker were less often prescribed in the
28
29
30 functional decline group than in the no functional decline group (Table 2).
31
32
33

34 **Long-term outcomes: functional decline vs. no functional decline groups**

35
36
37 Follow-up rate at 1-year was 96%. The cumulative 1-year incidence of the primary
38
39
40 outcome measure (a composite of all-cause death or heart failure hospitalization) in the
41
42
43 functional decline group was significantly higher than that in the no functional decline group
44
45
46 (50% vs. 31%, log-rank $P < 0.001$) (Figure 3). After adjusting for baseline characteristics, the
47
48
49 higher risk of the functional decline group relative to the no functional decline group
50
51
52 remained significant (adjusted HR, 1.50; 95%CI, 1.29–1.75; $P < 0.001$) (Figure 3 and eTable
53
54
55
56
57 2). The cumulative 1-year incidence of all-cause death was also significantly higher in the
58
59
60

1
2
3
4 functional decline group than in the no functional decline group. Even after adjusting
5
6
7
8 confounders, the excess mortality risk of the functional decline group relative to the no
9
10
11 functional decline group remained significant (Figure 3 and eTable 2). The cumulative 1-year
12
13
14 incidence of heart failure hospitalization was also significantly higher in the functional
15
16
17 decline group than in the no functional decline group. However, the adjusted risk of the
18
19
20 functional decline group relative to the no functional decline group for heart failure
21
22
23 hospitalization was no longer significant (Figure 3 and eTable 2). In the subgroup analyses,
24
25
26 there were no interactions between those subgroup factors and the association of functional
27
28
29 decline with the primary outcome measure (eFigure 2).
30
31
32
33

34 **Additional analysis on the risk factors for functional decline or in-hospital mortality**

35
36
37 The risk factors for functional decline or in-hospital mortality in a total of 4056
38
39
40 patients were similar to the risk factors for functional decline. LVEF <40% (OR, 1.23; 95%
41
42
43 CI, 1.00–1.52) and acute coronary syndrome (OR, 1.73; 95% CI, 1.17–2.56) that were not
44
45
46 included in the risk factors for functional decline emerged as the risk factors for functional
47
48
49 decline or in-hospital mortality. Meanwhile, among the risk factors for functional decline,
50
51
52 women (OR, 1.10; 95% CI, 0.90–1.34) was not included in the risk factors for functional
53
54
55 decline or in-hospital mortality (Figure 2 and eTable 1).
56
57
58
59
60

Discussion

The main findings of the present study investigating the prevalence and risk factors of functional decline during hospitalization, and its relationship with post-discharge outcomes in patients with ADHF hospitalization were as follows; 1) Functional decline during hospitalization occurred in 15% of patients, and 80% of those with functional decline were ambulatory before admission; 2) The independent baseline risk factors associated with functional decline included age ≥ 80 years, women, prior stroke, dementia, body temperature $\geq 37.5^{\circ}\text{C}$, hyponatremia, decreased albumin levels, eGFR < 30 ml/min/1.73m², and NYHA class III/IV; 3) Functional decline during the index hospitalization was associated with higher long-term risk for a composite of all-cause death or heart failure hospitalization.

This is the first large-scale contemporary multicentre study reporting the prevalence of functional decline in patients hospitalized for ADHF. Of note, we identified the severity of symptoms or patient status specific for heart failure was associated with functional decline independent of well-known factors in acute medical illness [16–18]. Functional decline is an inevitable consequence in aged people, but hospitalization accelerates the decline [18–20]. Functional declines have been found to be related not only to impairment of

1
2
3
4 independence and quality of life (QOL), but also to increased health service use, higher risk
5
6
7 for institutionalization, and higher risk for mortality [21–25]. Indeed, in the present study, the
8
9
10 proportion of patients discharged to home was lower in the functional decline group than in
11
12
13 the no functional decline group, suggesting impaired QOL after discharge. Also, the
14
15
16 long-term mortality was worse in the functional decline group than in the no functional
17
18
19 decline group. Therefore, it is important to recognize risk factors of functional decline. In
20
21
22 previous studies of hospitalized patients with acute medical illness, the predictors of
23
24
25 functional decline in hospitalized elderly patients were older age, admission diagnosis, lower
26
27
28 functional status, impaired cognitive status, comorbidities, and length of hospital stay [16–
29
30
31 18]. These findings were confirmed in the setting of ADHF in our present study. In addition,
32
33
34 findings specific for ADHF such as the dyspnoea or hyponatremia was associated with
35
36
37 functional decline, which were also reported to be the risk factors for in-hospital mortality in
38
39
40 ADHF [26]. The prevalence of dyspnoea, oedema, general malaise and loss of appetite at
41
42
43 discharge was higher in the functional decline group. Early achievement of successful ADHF
44
45
46 treatment might reduce the risk of functional decline, although the present observational
47
48
49 study could not address the cause-effect relationship between the functional decline and the
50
51
52 symptomatic status at discharge.
53
54
55
56
57
58
59
60

1
2
3
4 There might be several possible strategies to prevent functional decline during
5
6
7
8 ADHF hospitalization. The first is the early improvement of hemodynamic status to avoid
9
10
11 worsening heart failure. The prevalence of worsening heart failure was higher in the
12
13
14 functional decline group. As functional decline associated with hospitalization begins within
15
16
17 48 hours of admission, early improvement of heart failure to reduce the incidence of
18
19
20 hospitalization-associated disability is one of the main goals of care [26]. Second, it would be
21
22
23 important to be adequately aware high-risk patients to make aggressive intervention for
24
25
26 preventing functional decline. We identified the risk factors among the baseline
27
28
29 characteristics in ADHF patients. In addition, the adverse events during hospitalization may
30
31
32 be tightly related to the functional decline. Stroke is one of causes of functional decline and
33
34
35 observed in 5.1% of patients with functional decline. Third, a strategy for the prevention of
36
37
38 functional decline might be the seamless rehabilitation and comprehensive geriatric
39
40
41 management through a multidisciplinary team approach [27–30]. In addition, the subgroup
42
43
44 analysis showed that there were no interactions between those subgroup factors and the
45
46
47 association of functional decline with the primary outcome measure. Thus, prevention of
48
49
50 functional decline would have an impact on improving outcomes in all of the patients with
51
52
53 ADHF.
54
55
56
57
58
59
60

1
2
3
4 This study has several limitations. First, we did not collect information on activity
5
6
7 of daily living index. Instead, we adopted easy and simple classification of functional status
8
9
10 as ambulatory, use of wheelchair outdoor only, use of wheelchair indoor and outdoor, and
11
12
13 bedridden state. Second, we did not collect data regarding on-site and outpatient
14
15
16 rehabilitation and nutritional support. However, a team-based approach for heart failure
17
18 patients was adapted in all the participating centres in the present study. Third, we did not
19
20
21 include the status at discharge or adverse in-hospital events in the analysis for the risk factor
22
23
24 for functional decline, because the cause-effect relationship was not clear. Fourth, data on
25
26
27 post-discharge medication and change of functional status after discharge from the index
28
29
30 hospitalization were not collected, and not analysed in the analysis for the long-term
31
32
33 outcomes. Fifth, as with any observational study, the possibility of selection bias and residual
34
35
36 confounding cannot be excluded, although we adjusted for 23 variables as most conceivable
37
38
39 confounders.
40
41
42
43
44
45
46

47 **Conclusions**

48
49
50
51 Independent risk factors of functional decline in ADHF patients were related to
52
53
54 both frailty and severity of heart failure. Functional decline during ADHF hospitalization was
55
56
57 associated with unfavourable post-discharge outcomes.
58
59
60

Acknowledgment

H.Yaku and T.Kato had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

We gratefully acknowledge the contributions from KCHF study investigators (Hidenori Yaku, MD; Takao Kato, MD; Neiko Ozasa, MD; Erika Yamamoto, MD; Yusuke Yoshikawa, MD; Tetsuo Shioi, MD; Koichiro Kuwahara, MD; Takeshi Kimura, MD, at Kyoto University Hospital, Kyoto, Japan, Moritake Iguchi, MD; Yugo Yamashita, MD, Masaharu Akao, MD, at National Hospital Organization Kyoto Medical Center, Kyoto, Japan, Masashi Kato, MD; Shinji Miki, MD, at Mitsubishi Kyoto Hospital, Kyoto, Japan, Mamoru Takahashi, MD, at Shimabara Hospital, Kyoto, Japan, Tsuneaki Kawashima, MD; Takafumi Yagi, MD, at Daini Okamoto General Hospital, Toshikazu Jinnai, MD; Takashi Konishi, MD, at Japanese Red Cross Otsu Hospital, Otsu, Japan, Yasutaka Inuzuka, MD; Shigeru Ikeguchi, MD, at Shiga General Hospital, Moriyama, Japan, Tomoyuki Ikeda, MD; Yoshihiro Himura, MD, at Hikone Municipal Hospital, Hikone, Japan, Kazuya Nagao, MD; Tsukasa Inada, MD, at Osaka Red Cross Hospital, Osaka, Japan, Kenichi Sasaki, MD; Moriaki Inoko, MD, at Kitano Hospital, Osaka, Japan, Takafumi Kawai, MD; Tomoki Sasa, MD; Mitsuo Matsuda, MD, at Kishiwada City Hospital, Kishiwada, Japan, Akihiro Komasa, MD; Katsuhisa Ishii, MD, at

1
2
3
4 Kansai Electric Power Hospital, Osaka, Japan, Yodo Tamaki, MD; Yoshihisa Nakagawa,
5
6
7 MD, at Tenri Hospital, Tenri, Japan, Ryoji Taniguchi, MD; Yukihito Sato, MD; Yoshiki
8
9
10 Takatsu, MD, at Hyogo Prefectural Amagasaki General Medical Center, Amagasaki, Japan,
11
12
13 Takeshi Kitai, MD; Ryousuke Murai, MD; Yutaka Furukawa, MD, at Kobe City Medical
14
15
16
17 Center General Hospital, Kobe, Japan, Mitsunori Kawato, MD, at Kobe City Nishi-Kobe
18
19
20 Medical Center, Kobe, Japan, Yasuyo Motohashi, MD; Kanae Su, MD; Mamoru Toyofuku,
21
22
23
24 MD; Takashi Tamura, MD, at Japanese Red Cross Wakayama Medical Center, Wakayama,
25
26
27 Japan, Reiko Hozo, MD; Ryusuke Nishikawa, MD; Hiroki Sakamoto, MD, at Shizuoka
28
29
30 General Hospital, Shizuoka, Japan, Yuichi Kawase, MD; Keiichiro Iwasaki, MD; Kazushige
31
32
33
34 Kadota, MD, at Kurashiki Central Hospital, Kurashiki, Japan, and Takashi Morinaga, MD;
35
36
37
38 Yohei Kobayashi, MD; Kenji Ando, MD, at Kokura Memorial Hospital, Kokura, Japan.).
39
40
41
42
43

44 **Sources of Funding**

45
46
47 This study is supported by a grant from the Japan Agency for Medical Research and
48
49
50 Development (18059186) to T.K., K.K., N.O.. The founder had no role in the study design,
51
52
53
54 collection, analysis or interpretation of the data, writing the manuscript, or the decision to
55
56
57
58 submit the paper for publication.
59
60

Disclosures

None

Affiliations

From Kyoto University Graduate School of Medicine, Kyoto, Japan (H.Y., T.Kato, N.O., E.Y., Y.Y., S.S., K.O., T.Kimura); Hyogo College of Medicine, Nishinomiya, Japan (T.M.); Shiga General Hospital, Moriyama, Japan (Y.I.); Tenri Hospital, Tenri, Japan (Y.T., Y.N.); Kobe City Medical Center General Hospital, Kobe, Japan (T.K., Y.F.); Hyogo Prefectural Amagasaki General Medical Center, Amagasaki, Japan (R.Y., Y.S.); National Hospital Organization Kyoto Medical Center, Kyoto, Japan (M.I.); Mitsubishi Kyoto Hospital, Kyoto, Japan (K.M.); Japanese Red Cross Otsu Hospital, Otsu, Japan (T.J.); Hikone Municipal Hospital, Hikone, Japan (T.I.); Japanese Red Cross Osaka Hospital, Osaka, Japan (K.N.); Kishiwada City Hospital, Kishiwada, Japan (T.K.); Kansai Electric Power Hospital, Osaka, Japan (A.K.); Shizuoka General Hospital, Shizuoka, Japan (R.N.); Kurashiki Central Hospital, Kurashiki, Japan (Y.K., K.K.); Kokura Memorial Hospital, Kitakyushu, Japan (T. M., K.A.); Kitano Hospital, Osaka, Japan (Y.S.); Japanese Red Cross Wakayama Medical Center, Wakayama, Japan (M.T.); Shinshu University Graduate School of Medicine, Matsumoto, Japan (K.K.) .

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

References

- 1 Manton KG. A longitudinal study of functional change and mortality in the United States. *J Gerontol* 1988;**43**:S153-61.
- 2 Boyd CM, Ricks M, Fried LP, *et al.* Functional decline and recovery of activities of daily living in hospitalized, disabled older women: the Women's Health and Aging Study I. *J Am Geriatr Soc* 2009;**57**:1757–66. doi:10.1111/j.1532-5415.2009.02455.x
- 3 Guralnik JM, Alexih L, Branch LG. Medical and Long-Term Care Costs When Older Persons Become More Dependent Intentional Weight Loss and 13-Year Diabetes Incidence in Overweight Adults. *Am J Public Health* 2002;**92**:1244–5.
- 4 Gill TM, Allore HG, Holford TR, *et al.* Hospitalization, restricted activity, and the development of disability among older persons. *J Am Med Assoc* 2004;**292**:2115–24. doi:10.1001/jama.292.17.2115
- 5 Sager MA, Franke T, Inouye SK, *et al.* Functional outcomes of acute medical illness and hospitalization in older persons. *Arch Intern Med* 1996;**156**:645–52.
- 6 Japan's ethical guidelines for epidemiologic research. 2008;**2002**.http://www.lifescience.mext.go.jp/files/pdf/n796_01.pdf
- 7 45 Code of Federal Regulations 46.116(d). 2009;:4–

- 1
2
3
4 5. <https://www.hhs.gov/ohrp/regulations-and-policy/regulations/45-cfr-46/index.html#4>
5
6
7
8 6.116
9
10
11 8 Yamamoto E, Kato T, Ozasa N, *et al.* Kyoto Congestive Heart Failure (KCHF) study:
12
13 rationale and design. *ESC Hear Fail* 2017;**4**:216–23. doi:10.1002/ehf2.12138
14
15
16
17 9 Yaku H, Ozasa N, Morimoto T, *et al.* Demographics, Management, and In-Hospital
18
19 Outcome of Hospitalized Acute Heart Failure Syndrome Patients in Contemporary
20
21 Real Clinical Practice in Japan - Observations From the Prospective, Multicenter
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- 10 Butler J, Gheorghiade M, Kelkar A, *et al.* In-hospital worsening heart failure. *Eur J Heart Fail* 2015;**17**:1104–13. doi:10.1002/ejhf.333
- 11 Filippatos G, Farmakis D, Parissis J. Renal dysfunction and heart failure: Things are seldom what they seem. *Eur Heart J* 2014;**35**:416–8. doi:10.1093/eurheartj/ehf515
- 12 Vardeny O, Wu DH, Desai A, *et al.* Influence of baseline and worsening renal function on efficacy of spironolactone in patients with severe heart failure: Insights from rales (randomized aldactone evaluation study). *J Am Coll Cardiol* 2012;**60**:2082–9. doi:10.1016/j.jacc.2012.07.048

- 1
2
3
4 13 Clark H, Krum H, Hopper I. Worsening renal function during
5
6
7
8 renin-angiotensin-aldosterone system inhibitor initiation and long-term outcomes in
9
10
11 patients with left ventricular systolic dysfunction. *Eur J Heart Fail* 2014;**16**:41–8.
12
13
- 14 14 Ponikowski P, Voors AA, Anker SD, *et al.* 2016 ESC Guidelines for the diagnosis and
15
16
17 treatment of acute and chronic heart failure: The Task Force for the diagnosis and
18
19
20 treatment of acute and chronic heart failure of the European Society of Cardiology
21
22
23 (ESC). Developed with the special contribution . *Eur J Heart Fail* 2016;**18**:891–975.
24
25
26
27 doi:10.1002/ejhf.592
28
29
- 30 15 Oda E, Oohara K, Abe A, *et al.* The optimal cut-off point of C-reactive protein as an
31
32
33 optional component of metabolic syndrome in Japan. *Circ J* 2006;**70**:384–8.
34
35
36
37 doi:10.1253/circj.70.384
38
39
- 40 16 Stuck AE, Walthert JM, Nikolaus T, *et al.* Risk factors for functional status decline in
41
42
43 community-living elderly people: a systematic literature review. *Soc Sci Med*
44
45
46
47 1999;**48**:445–69. doi:10.1016/S0277-9536(98)00370-0
48
49
- 50 17 McCusker J, Kakuma R, Abrahamowicz M. Predictors of functional decline in
51
52
53 hospitalized elderly patients: a systematic review. *J Gerontol A Biol Sci Med Sci*
54
55
56
57 2002;**57**:M569-77.
58
59
60

- 1
2
3
4 18 Covinsky KE, Palmer RM, Fortinsky RH, *et al.* Loss of independence in activities of
5
6
7
8 daily living in older adults hospitalized with medical illnesses: increased vulnerability
9
10
11 with age. *J Am Geriatr Soc* 2003;**51**:451–8.
12
13
14 19 Inouye SK, Bogardus ST, Baker DI, *et al.* The hospital elder life program: A model of
15
16
17 care to prevent cognitive and functional decline in older hospitalized patients. *J Am*
18
19
20 *Geriatr Soc* 2000;**48**:1697–706. doi:10.1111/j.1532-5415.2000.tb03885.x
21
22
23
24 20 Pandharipande PP, Girard TD, Jackson JC, *et al.* Long-term cognitive impairment after
25
26
27 critical illness. *N Engl J Med* 2013;**369**:1306–16. doi:10.1056/NEJMoa1301372
28
29
30
31 21 Hirvensalo M, Rantanen T, Heikkinen E. Mobility difficulties and physical activity as
32
33
34 predictors of mortality and loss of independence in the community-living older
35
36
37 population. *J Am Geriatr Soc* 2000;**48**:493–8.
38
39
40
41 doi:10.1111/j.1532-5415.2000.tb04994.x
42
43
44 22 Greiner PA, Snowdon DA, Schmitt FA. The loss of independence in activities of daily
45
46
47 living: The role of low normal cognitive function in elderly nuns. *Am J Public Health*
48
49
50
51 1996;**86**:62–6. doi:10.2105/AJPH.86.1.62
52
53
54 23 Ganguli M, MPH ES, PhD SB, *et al.* Cognitive Impairment and the Use of Health
55
56
57 Services in an Elderly Rural Population: The MoVIES Project. *J Am Geriatr Soc*
58
59
60

- 1
2
3
4 1993;**41**:1065–70. doi:10.1111/j.1532-5415.1993.tb06453.x
5
6
7
8 24 Barberger-Gateau P, Fabrigoule C. Disability and cognitive impairment in the elderly.
9
10
11 *Disabil Rehabil* 1997;**19**:175–93.
12
13
14 25 Black SA, Rush RD. Cognitive and functional decline in adults aged 75 and older. *J*
15
16
17 *Am Geriatr Soc* 2002;**50**:1978–86. doi:10.1046/j.1532-5415.2002.50609.x
18
19
20
21 26 Hirsch CH, Sommers L, Olsen A, *et al*. The natural history of functional morbidity in
22
23
24 hospitalized older patients. *J Am Geriatr Soc* 1990;**38**:1296–303.
25
26
27
28 27 O'Connor CM, Whellan DJ, Lee KL, *et al*. Efficacy and safety of exercise training in
29
30
31 patients with chronic heart failure: HF-ACTION randomized controlled trial. *JAMA*
32
33
34 2009;**301**:1439–50. doi:10.1001/jama.2009.454
35
36
37
38 28 Baztán JJ, Suárez-García FM, López-Arrieta J, *et al*. Effectiveness of acute geriatric
39
40
41 units on functional decline, living at home, and case fatality among older patients
42
43
44 admitted to hospital for acute medical disorders: Meta-analysis. *BMJ* 2009;**338**:334–6.
45
46
47
48 doi:10.1136/bmj.b50
49
50
51 29 Fox MT, Persaud M, Maimets I, *et al*. Effectiveness of acute geriatric unit care using
52
53
54 acute care for elders components: A systematic review and meta-analysis. *J Am*
55
56
57 *Geriatr Soc* 2012;**60**:2237–45. doi:10.1111/jgs.12028
58
59
60

- 1
2
3
4 30 Bachmann S, Finger C, Huss A, *et al.* Inpatient rehabilitation specifically designed for
5
6
7 geriatric patients: Systematic review and meta-analysis of randomised controlled trials.
8
9

10
11 *BMJ* 2010;**340**:1230. doi:10.1136/bmj.c1718
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3
4 **Figure legends**
5

6
7 **Figure 1. Patient Flowchart.** KCHF=Kyoto Congestive Heart Failure, ADHF=acute
8
9
10
11 decompensated heart failure.
12

13
14 **Figure 2. Clinical Factors Associated with Functional Decline during Hospitalization in**
15
16
17 **the Univariate and Multivariable Logistic Regression Models.** BMI=body mass index,
18
19
20
21 LVEF=left ventricular ejection, HF=heart failure, eGFR=estimated glomerular filtration rate,
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
BP=blood pressure, NYHA=New York Heart Association, OR=odds ratio, CI=confidence
interval.

31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Figure 3. The Cumulative Incidences for the Primary Outcome Measure (A), for
All-cause Death (B), and for HF Hospitalization (C) According to the Presence or
Absence of Functional Decline. HF=heart failure, HR=hazard ratio, CI=confidence interval.

Table 1. Baseline Patient Characteristics

	Functional decline	No functional decline	P value
	N=528	N=3027	
Baseline characteristics			
Age, years	85 [80–89]	79 [70–85]	<0.001
Age ≥80 years*	399 (76)	1407 (46)	<0.001
Women*	294 (56)	1278 (42)	<0.001
BMI, kg/m ²	22.0±4.0	23.1±4.5	<0.001
BMI ≤22 kg/m ² *	269 (55)	1281 (44)	<0.001
Medical history			
Prior HF hospitalization*	186 (36)	1077 (36)	0.92
Atrial fibrillation/flutter*	220 (42)	1263 (42)	0.98
Hypertension*	406 (77)	2174 (72)	0.02
Diabetes mellitus*	187 (35)	1145 (38)	0.29
Prior myocardial infarction*	112 (21)	681 (23)	0.51
Prior stroke*	125 (24)	432 (14)	<0.001
Current smoking*	28 (5.5)	425 (14)	<0.001
Malignancy	97 (18)	419 (14)	0.006
Chronic lung disease*	41 (7.8)	247 (8.2)	0.76
Dementia*	175 (33)	423 (14)	<0.001
Social backgrounds			
Poor medical adherence	100 (19)	498 (16)	0.16
Living alone*	127 (24)	652 (22)	0.20
Public assistance	24 (4.6)	186 (6.1)	0.14
Functional status before admission			
Ambulatory	420 (80)	2529 (84)	0.02
Use of wheelchair [outdoor only]	80 (15)	192 (6.3)	<0.001
Use of wheelchair [outdoor and indoor]	28 (5.3)	306 (10)	<.0001
Underlying heart disease			
Ischemic	134 (25)	820 (27)	0.41

Acute coronary syndrome*	36 (6.8)	166 (5.5)	0.22
Hypertensive	131 (25)	754 (25)	0.96
Valvular	124 (23)	565 (19)	<0.001
Cardiomyopathy	54 (10)	492 (16)	<0.001

Clinical signs and symptoms at presentation

Orthopnoea (moderate or severe)	321 (64)	1743 (60)	0.09
Rales (moderate or severe)	302 (59)	1522 (52)	0.002
Systolic BP, mmHg	144±32	149±35	0.003
Systolic BP ≥140 mmHg	275 (53)	1741 (58)	0.03
Systolic BP <90 mmHg*	12 (2.3)	76 (2.5)	0.76
Diastolic BP, mmHg	81±23	86±24	<0.001
Heart rate, beat/min	93±27	96±28	0.001
Heart rate <60 beat/min*	44 (8.5)	195 (6.5)	0.11
Body temperature, °C	36.6±0.7	36.5±0.6	<0.001
Body temperature ≥37.5°C*	58 (11)	154 (5.3)	<0.001

Data on admission

Orthopnoea (moderate or severe)	208 (44)	1090 (40)	0.08
Rales (moderate or severe)	213 (47)	1021 (39)	0.001
Systolic BP, mmHg			
Systolic BP ≥140 mmHg	198 (38)	1199 (40)	0.29
Systolic BP <90 mmHg	8 (66)	58 (2.0)	0.51
Heart rate, beat/min	86±21	89±23	0.03

Echocardiography and Laboratory tests

LVEF	48±16	46±16	0.02
HF _r EF (EF<40%)*	167 (32)	1148 (38)	0.006
HF _{mr} EF (EF 40–49%)	117 (22)	566 (19)	0.06
HF _p EF (EF ≥50%)	242 (46)	1305 (43)	0.24
Haemoglobin, g/dL	11.0±2.1	11.7±2.4	<0.001
Anaemia*†	401 (76)	1946 (64)	<0.001
BNP, pg/ml	782 [448–1410]	687 [375–1214]	<0.001
NT-pro BNP, pg/ml	10795 [3450–18000]	5416 [2629–11438]	0.001
Creatinine, mg/dL	1.2 [0.8–1.6]	1.1 [0.8–1.6]	0.21
eGFR, ml/min/1.73m ²	38 [24–54]	46 [30–62]	<0.001

eGFR <30 ml/min/1.73m ² *	195 (37)	747 (25)	<0.001
Blood urea nitrogen, mg/dL	28 (20–39)	23 (17–33)	<0.001
Albumin, g/dL	3.3±0.5	3.5±0.5	<0.001
Albumin <3.0 g/dL*	112 (22)	332 (11)	<0.001
Sodium, mEq/L	138±4.7	139±4.1	<0.001
Sodium <135 mEq/L*	83 (16)	325 (11)	0.001
Potassium, mEq/L	4.3±0.8	4.2±0.6	0.03

Continuous variables were presented as mean ± SD or median with [interquartile range].

Categorical variables were presented as number (percentage).

* Risk-adjusting variables selected for Cox proportional hazard models.

† Defined by the World Health Organization criteria (haemoglobin <12 g/dL for women and <13 g/dL for men).

BMI=body mass index, HF=heart failure, BP=blood pressure, LVEF=left ventricular ejection fraction, HFrEF=heart failure with reduced ejection fraction, HFmrEF=heart failure with mid-range ejection fraction, HFpEF=heart failure with preserved ejection fraction, BNP=brain-type natriuretic peptide, NT-proBNP=N-terminal pro brain-type natriuretic peptide, eGFR=estimated glomerular filtration rate.

Table 2. In-hospital Management and Outcome

	Functional decline	No functional decline	P value
	N=528	N=3027	
In-hospital management			
Management in the emergency room			
Respiratory management			
Oxygen inhalation	295 (56)	1382 (46)	<0.001
NPPV	82 (16)	423 (14)	0.35
Intubation	11 (2.1)	53 (1.8)	0.60
Intravenous drugs within 24 hours after hospital presentation			
Inotropes	101 (19)	405 (13)	<0.001
Furosemide	446 (85)	2536 (84)	0.69
In-hospital clinical outcomes			
In-hospital adverse events			
Stroke	27 (5.1)	26 (0.9)	<0.001
Worsening heart failure	130 (25)	490 (16)	<0.001
Worsening renal function	244 (47)	992 (33)	<0.001
In-hospital infection	104 (20)	258 (8.5)	<0.001
Length of stay, day	21 [14–37]	15 [11–22]	<0.001
Clinical signs and symptoms at discharge			
Dyspnoea on exertion	206 (41)	731 (25)	<0.001
Oedema	89 (17)	320 (11)	<0.001
General malaise	152 (31)	388 (14)	<0.001
Loss of appetite	119 (24)	251 (8.7)	<0.001
Living place after discharge			
Home	247 (47)	2709 (90)	<0.001
Hospital	225 (43)	180 (6.0)	<0.001
Institution for the aged	50 (9.5)	114 (3.8)	<0.001
Other	4 (0.8)	17 (0.6)	0.59
Medications at discharge			
Number of drugs prescribed	8 (6–11)	9 (6–11)	0.12
Drugs			

1				
2				
3				
4	Loop diuretics	428 (81)	2472 (82)	0.74
5	RAAS inhibitors	349 (66)	2320 (77)	<0.001
6	ACEI/ARB	242 (46)	1838 (61)	<0.001
7	MRA	208 (39)	1409 (47)	0.002
8	Beta blocker	287 (54)	2101 (69)	<0.001
9	Tolvaptan	76 (14)	299 (9.9)	0.002
10				
11				
12				
13				
14				
15				
16				
17				
18				
19				
20				
21				
22				
23				
24				
25				
26				
27				
28				
29				
30				
31				
32				
33				
34				
35				
36				
37				
38				
39				
40				
41				
42				
43				
44				
45				
46				
47				
48				
49				
50				
51				
52				
53				
54				
55				
56				
57				
58				
59				
60				

For peer review only

KCHF registry
4056 patients hospitalized with ADHF
 (Oct 2014-Mar 2016, 19 centers in Japan)

In-hospital death during index hospitalization (N=271)

Excluded (N=230)
 No data about functional status (n = 99)
 Bedridden before index hospitalization (n = 131)

Study population:
Patients discharged alive assessed for functional decline during hospitalization
3555 patients

Functional decline: 528 patients

No functional decline: 3027 patients

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31


Variables	Unadjusted OR (95%CI)	P Value	Adjusted OR (95%CI)	P Value
Age ≥80 years	3.56 (2.88–4.40)	<0.001	2.56 (1.98–3.32)	<0.001
1 Women	1.72 (1.43–2.07)	<0.001	1.27 (1.01–1.60)	0.04
2 BMI ≤22	1.59 (1.31–1.93)	<0.001	1.20 (0.96–1.50)	0.11
4 LVEF <40%	0.76 (0.62–0.92)	0.006	1.14 (0.89–1.45)	0.29
5 Prior HF hospitalization	0.99 (0.82–1.20)	0.92	0.82 (0.65–1.04)	0.10
7 Acute coronary syndrome	1.26 (0.87–1.83)	0.22	1.53 (0.97–2.43)	0.07
8 Hypertension	1.31 (1.05–1.62)	0.02	1.11 (0.85–1.44)	0.46
10 Diabetes mellitus	0.90 (0.74–1.09)	0.29	1.03 (0.81–1.31)	0.81
11 Atrial fibrillation or flutter	1.00 (0.83–1.20)	0.98	1.02 (0.81–1.29)	0.85
12 Prior myocardial infarction	0.93 (0.74–1.16)	0.51	0.90 (0.69–1.19)	0.47
14 Prior stroke	1.86 (1.49–2.33)	<0.001	1.61 (1.23–2.10)	<0.001
15 Chronic lung disease	1.07 (0.82–1.40)	0.61	1.14 (0.83–1.56)	0.41
17 Cognitive dysfunction	3.05 (2.48–3.76)	<0.001	1.95 (1.52–2.52)	<0.001
18 Current smoking	0.35 (0.23–0.51)	<0.001	0.56 (0.36–0.88)	0.01
20 Living alone	1.15 (0.93–1.43)	0.20	1.20 (0.93–1.56)	0.17
21 Anemia	1.74 (1.1–2.16)	<0.001	1.10 (0.84–1.44)	0.48
23 Albumin <3.0 g/dL	2.16 (1.71–2.75)	<0.001	1.69 (1.27–2.24)	<0.001
24 Sodium <135 mEq/L	1.55 (1.19–2.01)	0.001	1.46 (1.07–1.98)	0.02
25 eGFR <30 ml/min/1.73m ²	1.79 (1.47–2.18)	<0.001	1.54 (1.21–1.96)	<0.001
27 Systolic BP <90 mmHg	0.91 (0.49–1.68)	0.76	0.61 (0.26–1.43)	0.25
28 Heart rate <60 beat/min	1.33 (0.95–1.87)	0.10	1.12 (0.75–1.69)	0.57
30 Body temperature ≥37.5 °C	2.30 (1.67–3.16)	<0.001	1.88 (1.29–2.74)	<0.001
32 NYHA III/IV on admission	1.81 (1.30–2.52)	<0.001	1.51 (1.05–2.18)	0.03

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>



Figure 3A


All cause death or HF hospitalization



Interval	0-day	30-day	180-day	1-year
No functional decline				
N of patients with at least 1 event	159	337	487	
N of patients at risk	2987	2623	2419	1934
Cumulative incidence	5.3%	18%	31%	
Functional decline				
N of patients with at least 1 event	58	170	242	
N of patients at risk	505	443	320	268
Cumulative incidence	12%	34%	50%	

Figure 3B


All cause death



Interval	0-day	30-day	180-day	1-year
No functional decline				
N of patients with event	33	190	284	
N of patients at risk	2987	2642	2739	2289
Cumulative incidence	1.1%	6.8%	13%	
Functional decline				
N of patients with event	32	115	174	
N of patients at risk	505	486	372	280
Cumulative incidence	6.4%	24%	38%	

Figure 3C

HF hospitalization



Interval	0-day	30-day	180-day	1-year
No functional decline				
N of patients with at least 1 event	138	417	669	
N of patients at risk	2987	2825	2419	1934
Cumulative incidence	4.6%	14%	23%	
Functional decline				
N of patients with at least 1 event	32	79	116	
N of patients at risk	505	443	320	268
Cumulative incidence	6.5%	17%	28%	

Figure 3. The Cumulative Incidences for the Primary Outcome Measure (A), for All-cause Death (B), and for HF Hospitalization (C) According to the Presence or Absence of Functional Decline.

90x134mm (300 x 300 DPI)

Supplementary Online Content

eTable 1. Clinical Factors associated with Functional Decline in the Entire Cohort in the Univariate and Multivariable Analyses

eTable 2. Clinical Outcomes in the Entire Cohort

eFigure 1. The Details of Functional Decline during ADHF Hospitalization.

eFigure 2. Subgroup Analysis for the Association of Functional Decline with no Functional Decline on the Primary Outcome Measure.

For peer review only

eTable 1. Clinical Factors associated with Functional Decline in the Entire Cohort in the Univariate and Multivariable Analyses

Variables	Unadjusted OR	P Value	Adjusted OR	P Value
Age ≥80 years	2.97 (2.50–3.52)	<0.001	2.25 (1.81–2.81)	<0.001
Women	1.45 (1.25–1.70)	<0.001	1.10 (0.90–1.34)	0.37
BMI ≤22	1.56 (1.32–1.83)	<0.001	1.19 (0.98–1.45)	0.08
LVEF <40%	1.04 (0.89–1.22)	0.61	1.23 (1.00–1.52)	0.048
Prior HF hospitalization	1.08 (0.92–1.27)	0.36	0.97 (0.79–1.19)	0.80
Acute coronary syndrome	1.56 (1.16–2.11)	0.003	1.73 (1.17–2.56)	0.006
Hypertension	1.00 (0.85–1.20)	0.95	0.97 (0.77–1.21)	0.76
Diabetes mellitus	0.86 (0.73–1.01)	0.06	0.88 (0.71–1.08)	0.22
Atrial fibrillation or flutter	0.97 (0.83–1.13)	0.67	0.91 (0.74–1.11)	0.33
Prior myocardial infarction	0.94 (0.78–1.13)	0.50	0.87 (0.69–1.11)	0.26
Prior stroke	1.73 (1.43–2.10)	<0.001	1.54 (1.21–1.94)	<0.001
Chronic lung disease	1.11 (0.89–1.39)	0.37	1.16 (0.89–1.52)	0.27
Cognitive dysfunction	2.91 (2.44–3.47)	<0.001	2.03 (1.63–2.53)	<0.001
Current smoking	0.37 (0.27–0.51)	<0.001	0.56 (0.38–0.82)	0.003
Living alone	1.05 (0.87–1.27)	0.62	1.19 (0.94–1.49)	0.14
Anaemia*	1.67 (1.39–1.98)	<0.001	1.07 (0.85–1.35)	0.56
Albumin <3.0 g/dL	2.30 (1.89–2.81)	<0.001	1.83 (1.44–2.33)	<0.001
Sodium <135 mEq/L	1.89 (1.53–2.33)	<0.001	1.68 (1.31–2.16)	<0.001
eGFR <30 ml/min/1.73m ²	2.01 (1.70–2.36)	<0.001	1.76 (1.43–2.17)	<0.001
Systolic BP <90 mmHg	2.01 (1.37–2.96)	<0.001	1.17 (0.67–2.05)	0.58
Heart rate <60 beat/min	1.07 (0.79–0.79)	0.66	1.03 (0.72–1.49)	0.87
Body temperature ≥37.5 °C	2.26 (1.72–2.7)	<0.001	1.89 (1.35–2.63)	<0.001
NYHA III/IV on admission	2.17 (1.62–2.91)	<0.001	1.69 (1.21–2.35)	0.002

Values are number (%), mean ± SD, or median (interquartile range).

*Defined by the World Health Organization criteria (hemoglobin <12 g/dL for women and <13 g/dL for men).

BMI=body mass index, LVEF=left ventricular ejection, HF=heart failure, eGFR=estimated glomerular filtration rate, BP=blood pressure, NYHA=New York Heart Association, OR=odds ratio, CI=confidence interval.

eTable 2. Clinical Outcomes in the Entire Cohort


Outcomes	Functional decline	No functional decline	Unadjusted HR (95% CI)	P value	Adjusted HR (95% CI)	P value
	N of patients with event/N of patients at risk (Cumulative 1- year incidence [%])	N of patients with event/N of patients at risk (Cumulative 1- year incidence [%])				
All-cause death or HF hospitalization	242/505 (50)	897/2987 (31)	1.94 (1.70–2.21)	<0.001	1.5 (1.29–1.75)	<0.001
All-cause death	174/505 (36)	384/2987 (13)	3.01 (2.57–3.53)	<0.001	2.14 (1.78–2.57)	<0.001
HF hospitalization	116/505 (28)	659/2987 (23)	1.26 (1.04–1.51)	0.01	1.07 (0.86–1.31)	0.55

The number of patients with at least one event was counted through the 1-year follow-up period.

HF=heart failure, HR=hazard ratio, CI=confidence interval, HF=heart failure.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

eFigure 1. The Details of Functional Decline during ADHF Hospitalization. Functional status at discharge according to functional status before admission is shown. ADHF=acute decompensated heart failure.



eFigure 2. Subgroup Analysis for the Association of Functional Decline with no Functional Decline on the Primary Outcome Measure. LVEF=left ventricular ejection

fraction, HR=hazard ratio, CI=confidence interval.

	Functional decline	Non-functional decline	Adjusted HR (95% CI)	P value for interaction
	No. Events/No. at risk	No. Events/No. at risk		
Age, years				
<80	58/122	375/1604	1.48 (1.08–2.02)	0.45
≥80	185/390	527/1401	1.44 (1.21–1.71)	
Sex				
Female	122/286	383/1271	1.43 (1.15–1.78)	0.24
Male	121/226	519/1734	1.64 (1.33–2.03)	
LVEF, %				
<40	75/159	371/1136	1.30 (0.98–1.69)	0.09
≥40	168/351	528/1861	1.65 (1.37–1.98)	
Anaemia				
No	47/123	210/1068	1.70 (1.17–2.41)	0.12
Yes	196/389	691/1931	1.44 (1.22–1.70)	
Albumin <3.0 g/dL				
No	169/394	760/2586	1.38 (1.16–1.64)	0.09
Yes	67/108	117/182	1.95 (1.40–2.69)	
Body temperature ≥37.5 °C				
No	211/433	815/2712	1.51 (1.29–1.76)	0.89
Yes	25/56	42/153	1.55 (0.84–2.78)	
Oedema at discharge				
No	184/408	739/2597	1.42 (1.20–1.68)	0.28
Yes	51/88	128/318	1.86 (1.23–2.80)	
General malaise at discharge				
No	142/320	690/2398	1.38 (1.15–1.67)	0.48
Yes	83/149	151/385	1.62 (1.18–2.21)	

STROBE Statement—Checklist of items that should be included in reports of *cohort studies*

	Item No	Recommendation
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract (b) Provide in the abstract an informative and balanced summary of what was done and what was found
Introduction		
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported
Objectives	3	State specific objectives, including any prespecified hypotheses
Methods		
Study design	4	Present key elements of study design early in the paper
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up (b) For matched studies, give matching criteria and number of exposed and unexposed
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group
Bias	9	Describe any efforts to address potential sources of bias
Study size	10	Explain how the study size was arrived at
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding (b) Describe any methods used to examine subgroups and interactions (c) Explain how missing data were addressed (d) If applicable, explain how loss to follow-up was addressed (e) Describe any sensitivity analyses
Results		
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed (b) Give reasons for non-participation at each stage (c) Consider use of a flow diagram
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders (b) Indicate number of participants with missing data for each variable of interest (c) Summarise follow-up time (eg, average and total amount)
Outcome data	15*	Report numbers of outcome events or summary measures over time
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included (b) Report category boundaries when continuous variables were categorized (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period

1	Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and
2			sensitivity analyses
3	<hr/>		
4	Discussion		
5	Key results	18	Summarise key results with reference to study objectives
6	Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or
7			imprecision. Discuss both direction and magnitude of any potential bias
8	<hr/>		
9	Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations,
10			multiplicity of analyses, results from similar studies, and other relevant evidence
11	<hr/>		
12	Generalisability	21	Discuss the generalisability (external validity) of the study results
13	<hr/>		
14	Other information		
15	Funding	22	Give the source of funding and the role of the funders for the present study and, if
16			applicable, for the original study on which the present article is based
17	<hr/>		

*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at <http://www.strobe-statement.org>.

BMJ Open

Risk factors and clinical outcomes of functional decline during acute decompensated heart failure hospitalization: an observational study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-032674.R1
Article Type:	Original research
Date Submitted by the Author:	27-Nov-2019
Complete List of Authors:	Yaku, Hidenori; Kyoto University Graduate School of Medicine Faculty of Medicine, Department of Cardiovascular Medicine; Mitsubishi Kyoto Hospital, Cardiology Kato, Takao; Kyoto University Graduate School of Medicine Faculty of Medicine, Department of Cardiovascular Medicine Morimoto, Takeshi; Hyogo College of Medicine, Clinical Epidemiology Inuzuka, Yasutaka; Shiga General Hospital, Cardiovascular Medicine Tamaki, Yodo; Public Interest Incorporated Foundation Tenri Hospital, Cardiology Ozasa, Neiko; Kyoto University Graduate School of Medicine Faculty of Medicine, Department of Cardiovascular Medicine Yamamoto, Erika; Kyoto University Graduate School of Medicine Faculty of Medicine, Department of Cardiovascular Medicine Yoshikawa, Yusuke; Kyoto University Graduate School of Medicine Faculty of Medicine, Department of Cardiovascular Medicine Kitai, Takeshi; Kobe City Medical Center General Hospital, Cardiovascular Medicine Kato, Masashi; Mitsubishi Kyoto Hospital, Department of Cardiology Ikeda, Tomoyuki; Hikone Municipal Hospital, Department of Cardiology Furukawa, Yutaka; Kobe City Medical Center General Hospital, Cardiovascular Medicine Nakagawa, Yoshihisa; Shiga University of Medical Science, Cardiovascular Medicine Sato, Yukihiro; Hyogo Prefectural Amagasaki General Medical Center, Cardiology Kuwahara, Koichiro ; Shinshu University Graduate School of Medicine School of Medicine, Cardiovascular Medicine Kimura, Takeshi; Kyoto University Graduate School of Medicine Faculty of Medicine, Department of Cardiovascular Medicine
Primary Subject Heading:	Cardiovascular medicine
Secondary Subject Heading:	Cardiovascular medicine
Keywords:	Heart failure < CARDIOLOGY, Adult cardiology < CARDIOLOGY, Cardiac Epidemiology < CARDIOLOGY

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60





I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3
4 **1 Risk factors and clinical outcomes of functional decline during acute decompensated**
5
6
7 **2 heart failure hospitalization: an observational study**
8
9
10
11
12

13 **4 Authors:** Hidenori Yaku, MD ^{a,f}, Takao Kato, MD ^a, Takeshi Morimoto, MD, MPH ^b,
14
15 Yasutaka Inuzuka, MD ^c, Yodo Tamaki, MD ^d, Neiko Ozasa, MD ^a, Erika Yamamoto, MD ^a,
16
17 Yusuke Yoshikawa, MD ^a, Takeshi Kitai, MD ^e, Masashi Kato, MD ^f, Tomoyuki Ikeda
18
19 ^g, Yutaka Furukawa, MD ^e, Yoshihisa Nakagawa, MD ^h, Yukihiro Sato, MD ⁱ, Koichiro
20
21
22
23 ⁸ Kuwahara, MD ^j, Takeshi Kimura, MD ^a, for the KCHF study investigators
24
25
26
27

28 **10 Affiliations:** ^a Department of Cardiovascular Medicine, Kyoto University Graduate School of
29
30
31
32 ¹¹ Medicine, Kyoto, Japan; ^b Department of Clinical Epidemiology, Hyogo College of
33
34
35 ¹² Medicine, Hyogo, Japan; ^c Department of Cardiovascular Medicine, Shiga General Hospital,
36
37
38 ¹³ Shiga, Japan; ^d Division of Cardiology, Tenri Hospital, Nara, Japan; ^e Department of
39
40
41
42 ¹⁴ Cardiovascular Medicine, Kobe City Medical Centre General Hospital, Hyogo, Japan; ^f
43
44
45 ¹⁵ Department of Cardiology, Mitsubishi Kyoto Hospital, Kyoto, Japan; ^g Department of
46
47
48 ¹⁶ Cardiology, Hikone Municipal Hospital, Shiga, Japan; ^h Department of Cardiovascular
49
50
51
52 ¹⁷ Medicine, Shiga University of Medical Science, Shiga, Japan; ⁱ Department of Cardiology,
53
54
55 ¹⁸ Hyogo Prefectural Amagasaki General Medical Centre, Hyogo, Japan; ^j Department of
56
57
58 ¹⁹ Cardiovascular Medicine, Shinshu University Graduate School of Medicine, Nagano, Japan.
59
60

1

2 **Corresponding Author:** Takao Kato, MD.

3 Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine

4 54 Shogoin Kawahara-cho, Sakyo-ku, Kyoto. 606-8507 Japan

5 Tel: +81-75-751-4254; FAX: +81-75-751-3289; E-mail: tkato75@kuhp.kyoto-u.ac.jp

6

7 **Manuscript word count:** 2903 words

8

1
2
3
4 **1 Abstract**

5
6
7 **2 Objective:** To investigate the prevalence and risk factors of functional decline during
8
9
10
11 **3** hospitalization, and its relationship with post-discharge outcomes in patients with acute
12
13
14 **4** decompensated heart failure (ADHF) hospitalization.

15
16
17 **5 Design:** Prospective cohort study between October 1, 2014, and March 31, 2016.

18
19
20
21 **6 Setting:** A physician-initiated multicentre study of consecutive patients admitted for ADHF
22
23
24 **7** into 19 hospitals throughout Japan.

25
26
27 **8 Participants:** Among 3555 patients hospitalized for ADHF (median age [IQR], 80 [71-86]
28
29
30
31 **9** years; 1572 [44%] women), functional decline during the index hospitalization occurred in
32
33
34 **10** 528 patients (15%).

35
36
37 **11 Primary and secondary outcomes:** The primary outcome measure was a composite of all-
38
39
40
41 **12** cause death or heart failure hospitalization after discharge. The secondary outcome measures
42
43
44 **13** were all-cause death, heart failure hospitalization, and a composite of all-cause death or all-
45
46
47 **14** cause hospitalization.

48
49
50
51 **15 Results:** The independent risk factors for functional decline included age ≥ 80 years (OR
52
53
54 **16** 2.56; 95% CI 1.98–3.32), women (OR 1.27; 95% CI 1.01–1.60), prior stroke (OR 1.61; 95%
55
56
57 **17** CI 1.23–2.10), dementia (OR 1.95; 95% CI 1.52–2.52), elevated body temperature (OR 1.88;
58
59
60

1
2
3
4 1 95% CI 1.29–2.74), hyponatremia (OR 1.46; 95% CI 1.07–1.98), decreased albumin levels
5
6
7
8 2 (OR 1.69; 95% CI 1.27–2.24), renal dysfunction (OR 1.54; 95% CI 1.21–1.96), and New
9
10
11 3 York Heart Association class III or IV on admission (OR 1.51; 95% CI 1.05–2.18) after
12
13
14 4 multivariable adjustment. The cumulative 1-year incidence of the primary outcome in the
15
16
17 5 functional decline group was significantly higher than that in the no functional decline group
18
19
20 6 (50% vs. 31%, log-rank $P < 0.001$). After adjusting for baseline characteristics, the higher risk
21
22
23
24 7 of the functional decline group relative to the no functional decline group remained
25
26
27 8 significant (adjusted HR 1.39; 95% CI 1.18–1.62; $P < 0.001$).

28
29
30
31 9 **Conclusions:** Independent risk factors of functional decline in ADHF patients were related to
32
33
34 10 both frailty and severity of heart failure. Functional decline during ADHF hospitalization was
35
36
37 11 associated with unfavourable post-discharge outcomes.

38
39
40
41 12 **Trial Registration:** <https://clinicaltrials.gov/ct2/show/NCT02334891> (NCT02334891) and
42
43
44 13 https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000017241
45
46
47 14 (UMIN000015238)

48
49
50 15
51
52
53
54
55
56
57
58
59
60

1 Strengths and limitations of this study

- 2 • This study is the first large-scale contemporary multicentre observational study reporting
3 the prevalence of functional decline in patients hospitalized for acute decompensated
4 heart failure (ADHF).
- 5 • The data of this study were prospectively collected on consecutive patients who had
6 hospital admission due to ADHF in the real-world clinical practice in Japan.
- 7 • This study examines the risk factors of functional decline in patients hospitalized for
8 ADHF, and whether functional decline during the index hospitalization was associated
9 with worse post-discharge outcomes.
- 10 • We did not collect data regarding on-site and outpatient rehabilitation and nutritional
11 support.

1 Introduction

2 Functional decline in hospitalized patients is a complex and dynamic process [1–3].
3 Functional decline during hospitalization was reported to occur in approximately 30-50% of
4 patients hospitalized for acute medical illness [2,4,5]. In the rapidly aging societies, the
5 number of patients hospitalized for acute decompensated heart failure (ADHF) is increasing,
6 and ADHF has become the leading cause of hospitalization due to acute medical illness. In
7 older patients, functional decline associated with hospitalization often leads to subsequent
8 inability to live actively and independently.

9 However, there is a scarcity of data regarding the risk factors of functional decline
10 in patients hospitalized for ADHF. Identifying high-risk patients for functional decline during
11 hospitalization would be useful for its prevention. Furthermore, no previous study focused on
12 subsequent clinical outcomes in patients with functional decline during hospitalization.

13 Therefore, we sought to clarify the risk factors for functional decline during hospitalization in
14 patients with ADHF and to compare the 1-year clinical outcomes between the 2 groups of
15 patients with and without functional decline during the hospitalization for ADHF in a large
16 Japanese observational database of hospitalized patients for ADHF in the real-world clinical
17 practice.

1 **Methods**

2 **Study Design, Setting, and Population**

3 The Kyoto Congestive Heart Failure (KCHF) registry is a physician-initiated,
4 prospective, observational, multicentre cohort study that enrolled consecutive patients who
5 were hospitalized for ADHF for the first time between October 1, 2014, and March 31, 2016.
6 These patients were admitted into 19 secondary and tertiary hospitals, including rural and
7 urban as well as large and small institutions, throughout Japan. The study protocol was
8 approved by the institutional review board of Kyoto University (approval number: E2311)
9 and each participating centre. A waiver of written informed consent from each patient was
10 granted by the institutional review boards of Kyoto University and each participating centre
11 because the study met the conditions of the Japanese ethical guidelines for epidemiological
12 study and the US policy for protecting human research participants.[6,7] This study followed
13 the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE)
14 reporting guideline.

15 The details of the KCHF study design and patient enrolment are described
16 elsewhere.[8–11] Briefly, we enrolled all patients with ADHF, as defined by the modified
17 Framingham criteria, who were admitted to the participating hospitals and patients who

1
2
3
4 1 underwent heart failure-specific treatment involving intravenous drugs within 24 hours after
5
6
7
8 2 hospital presentation. Patient records were anonymized before analysis. Data analysis was
9
10
11 3 conducted from August 2018 to October 2018.
12
13

14 4 Among 4056 patients enrolled in the KCHF registry, 3785 patients were discharged
15
16
17 5 alive after hospitalization for ADHF. Clinical follow-up data were collected in October 2017.
18
19
20
21 6 The attending physicians or research assistants at each participating hospital collected clinical
22
23
24 7 events after the index hospitalization from hospital charts or by contacting patients, their
25
26
27
28 8 relatives, or their referring physicians with consent. The present analysis had 2 objectives.
29
30
31 9 First, we sought to clarify the risk factors for functional decline during hospitalization of
32
33
34 10 ADHF patients. Second, we sought to compare the 1-year clinical outcomes between the 2
35
36
37
38 11 groups of patients with and without functional decline during the hospitalization for ADHF.
39
40
41 12 Among 4056 patients enrolled in the KCHF registry, the current study population consisted
42
43
44 13 of 3555 patients who were discharged alive and were assessed for functional decline during
45
46
47
48 14 hospitalization, excluding 271 patients who died during the index hospitalization, 99 patients
49
50
51 15 whose functional status before admission and/or at discharge was not available, and 131
52
53
54 16 patients who were bedridden before index hospitalization (Figure 1). The long-term follow-
55
56
57
58 17 up was censored at 1-year. The primary outcome measure in the current analysis was a
59
60

1
2
3
4 1 composite of all-cause death or heart failure hospitalization at 1-year. The secondary outcome
5
6
7
8 2 measures were all-cause death, heart failure hospitalization, and a composite of all-cause
9
10
11 3 death or all-cause hospitalization at 1-year.
12
13

14 **Definitions**

15
16
17 5 Physical activity before admission and at discharge was classified by mobility
18
19
20
21 6 status based on the definition of Japanese long-term care insurance into ambulatory
22
23
24 7 (including those patients using any aid such as stick), use of wheelchair outdoor only, use of
25
26
27
28 8 wheelchair indoor and outdoor, and bedridden state.[8] Functional decline was defined as the
29
30
31 9 decline of at least one stage on physical activity at discharge compared with pre-admission
32
33
34 10 status. In-hospital worsening heart failure was defined as additional intravenous drug
35
36
37
38 11 administration for heart failure, haemodialysis, or mechanical circulatory or respiratory
39
40
41 12 support, occurring >24 hours after therapy initiation.[12] In-hospital worsening renal function
42
43
44 13 was defined as >0.3 mg/dL increase in serum creatinine levels during the index
45
46
47
48 14 hospitalization.[13–15] Detailed definitions of baseline clinical characteristics including the
49
50
51 15 signs and symptoms of heart failure were described previously.[9] Missing values were
52
53
54 16 presented in eTable 1.
55
56

57 **Statistical Analysis**

1
2
3
4 1 Categorical variables were presented as numbers with percentages and compared
5
6
7
8 2 using χ^2 test. Continuous variables were expressed as the mean with standard deviation or
9
10
11 3 median with 25th to 75th percentiles, and compared using the Student's *t* test when normally
12
13
14 4 distributed or Wilcoxon rank-sum test when not normally distributed.
15
16

17
18 5 We compared baseline characteristics and clinical outcomes based on the presence
19
20
21 6 or absence of functional decline during the index hospitalization. A multivariable logistic
22
23
24 7 regression model was developed to identify clinical characteristics associated with an
25
26
27
28 8 increased risk for functional decline. We used 23 clinically relevant factors listed in Table 1
29
30
31 9 as potential independent risk factors in multivariable logistic regression models and estimated
32
33
34 10 the odd ratios (ORs) and 95% confidence intervals (CIs). We used the Kaplan-Meier method
35
36
37
38 11 to estimate the cumulative 1-year incidences of the outcome measures and assessed the
39
40
41 12 differences with the log-rank test. We expressed the associations of the functional decline
42
43
44 13 group with the no functional decline group for all outcome measures as hazard ratios (HRs)
45
46
47
48 14 with 95% CIs by multivariable Cox proportional hazard models incorporating 29 clinically
49
50
51 15 relevant risk-adjusting variables indicated in Table 1. We also conducted subgroup analyses
52
53
54 16 stratified by age, sex, LVEF, anaemia, albumin levels, body temperature, and the
55
56
57
58 17 symptomatic status at discharge (oedema and general malaise at discharge). In the
59
60

1 multivariable analysis and subgroup analyses, continuous variables were dichotomized by
2 clinically meaningful reference values or median values; age ≥ 80 years based on the median
3 value, LVEF $< 40\%$ based on the heart failure guideline of LVEF classification [16], BMI
4 ≤ 22 kg/m², renal dysfunction (eGFR < 30 ml/min/1.73m²) based on CKD grade, decreased
5 albumin levels (serum albumin < 3.0 g/dL), hyponatremia (serum sodium < 135 mEq/L),
6 elevated body temperature (body temperature $\geq 37.5^\circ\text{C}$) based on the cut-off value in
7 metabolic syndrome [17].

8 We performed an additional analysis using the data including those patients who
9 died during the index hospitalization and those who were bedridden before the index
10 hospitalization, and evaluated the factors associated with functional decline or in-hospital
11 mortality by constructing the multivariable adjusted Cox models. All statistical analyses were
12 conducted by a physician (H.Y.) and a statistician (T.M.) with JMP 13.0 or SAS 9.4 (both
13 SAS Institute Inc, Cary, NC). Two-tailed P-values less than 0.05 were considered statistically
14 significant.

15 **Patient and public involvement**

16 No patient involved.

17

1 **Results**

2 **Baseline Clinical Characteristics**

3 Among 3555 study patients, physical activity before admission included
4 ambulatory in 2949 patients (83%), wheelchair outdoor only in 272 patients (7.7%), and
5 wheelchair outdoor and indoor in 334 patients (9.4%). At hospital discharge, functional
6 decline was observed in 420 patients (14%) who were ambulatory before admission, in 80
7 patients (29%) who had used wheelchair outdoor only, and in 28 patients (8.4%) who had
8 used wheelchair outdoor and indoor. Consequently, decline in functional status was observed
9 in 528 patients (15%; functional decline group), while functional decline was not observed in
10 3027 patients (85%; no functional decline group) (eFigure 1). Wheelchair outdoor only
11 before admission were more prevalent in the functional decline group than in the no
12 functional decline group; however, 80% of patients in the functional decline group were
13 ambulatory before admission (Table 1).

14 Regarding the baseline clinical characteristics, the patients in the functional decline
15 group were older and had a higher prevalence of hypertension, prior stroke, renal
16 dysfunction, dementia, malignancy, anaemia, decreased albumin levels, and hyponatremia
17 (Table 1). There were no significant differences in previous heart failure hospitalization,

1 atrial fibrillation or flutter, previous myocardial infarction, chronic lung disease, and living
2 alone status as a social background between the 2 groups (Table 1). The functional decline
3 group was more likely to have a valvular aetiology, lower blood pressure, lower heart rate,
4 higher levels of brain natriuretic peptide (BNP) or N-terminal portion of proBNP (NT-
5 proBNP), and a higher LVEF (Table 1). The proportion of patients who achieved relief of
6 signs and symptoms on admission after the treatment in the emergency room was not
7 significantly different between the 2 groups (14% vs. 16%, P=0.25).

8 **Risk Factors for Functional Decline**

9 Among the baseline characteristics and status at hospital presentation, the following
10 independent risk factors for functional decline during hospitalization were identified by the
11 multivariable logistic regression analysis: age ≥ 80 years (OR 2.56; 95% CI 1.98–3.32),
12 women (OR 1.27; 95% CI 1.01–1.60), prior stroke (OR 1.61; 95% CI 1.23–2.10), dementia
13 (OR 1.95; 95% CI 1.52–2.52), elevated body temperature (OR 1.88; 95% CI 1.29–2.74),
14 hyponatremia (OR 1.46; 95% CI 1.07–1.98), decreased albumin levels (OR 1.69; 95% CI
15 1.27–2.24), eGFR < 30 ml/min/1.73m² (OR 1.54; 95% CI 1.21–1.96), and New York Heart
16 Association (NYHA) class III or IV on admission (OR 1.51; 95% CI 1.05–2.18) (Figure 2
17 and eTable 2).

1 **In-hospital adverse events and status at discharge**

2 The median length of hospital stay was longer in the functional decline group than
3 in the no functional decline group (21 days vs. 15 days, $P < 0.001$). Regarding the in-hospital
4 adverse events, the prevalence of worsening heart failure, worsening renal function, and
5 stroke was higher in the functional decline group than in the no functional decline group
6 (Table 2). The proportion of patients with symptoms such as oedema and general malaise at
7 discharge was higher in the functional decline group than in the no functional decline group
8 (Table 1). Consequently, the proportion of patients in the functional decline group discharged
9 to home was also lower (47% vs. 90%, $P < 0.001$). Regarding medical treatment at discharge,
10 angiotensin-converting enzyme inhibitor or angiotensin receptor blocker (ACEI or ARB), and
11 beta blocker were less often prescribed in the functional decline group than in the no
12 functional decline group (Table 1).

13 **Long-term outcomes: functional decline vs. no functional decline groups**

14 Follow-up rate at 1-year was 96%. The cumulative 1-year incidence of the primary
15 outcome measure (a composite of all-cause death or heart failure hospitalization) in the
16 functional decline group was significantly higher than that in the no functional decline group
17 (49% vs. 31%, log-rank $P < 0.001$) (Figure 3). After adjusting for baseline characteristics, the

1
2
3
4 1 higher risk of the functional decline group relative to the no functional decline group
5
6
7
8 2 remained significant (adjusted HR, 1.39; 95%CI, 1.18–1.62; $P<0.001$) (Figure 3 and eTable
9
10
11 3). The cumulative 1-year incidence of all-cause death was also significantly higher in the
12
13
14 4 functional decline group than in the no functional decline group. Even after adjusting
15
16
17 5 confounders, the excess mortality risk of the functional decline group relative to the no
18
19
20
21 6 functional decline group remained significant (Figure 3 and eTable 3). The cumulative 1-year
22
23
24 7 incidence of heart failure hospitalization was also significantly higher in the functional
25
26
27
28 8 decline group than in the no functional decline group. However, the adjusted risk of the
29
30
31 9 functional decline group relative to the no functional decline group for heart failure
32
33
34 10 hospitalization was no longer significant (Figure 3 and eTable 3). The cumulative 1-year
35
36
37
38 11 incidence of a composite of all-cause death or all-cause hospitalization was significantly
39
40
41 12 higher in the functional decline group than in the no functional decline group. After adjusting
42
43
44 13 confounders, the higher risk of the functional decline group relative to the no functional
45
46
47
48 14 decline group remained significant (Figure 3 and eTable 3). In the subgroup analyses, there
49
50
51 15 were no interactions between those subgroup factors and the association of functional decline
52
53
54 16 with the primary outcome measure (eFigure 2).

57 **Additional analysis on the risk factors for functional decline or in-hospital mortality**
58
59
60

1
2
3
4 1 The risk factors for functional decline or in-hospital mortality in a total of 4056
5
6
7
8 2 patients were similar to the risk factors for functional decline. LVEF <40% (OR, 1.23; 95%
9
10
11 3 CI, 1.00–1.52) and acute coronary syndrome (OR, 1.73; 95% CI, 1.17–2.56) that were not
12
13
14 4 included in the risk factors for functional decline emerged as the risk factors for functional
15
16
17 5 decline or in-hospital mortality. Meanwhile, among the risk factors for functional decline,
18
19
20
21 6 women (OR, 1.10; 95% CI, 0.90–1.34) was not included in the risk factors for functional
22
23
24 7 decline or in-hospital mortality (Figure 2 and eTable 2).
25
26
27
28 8
29
30

31 **Discussion**

32
33
34 10 The main findings of the present study investigating the prevalence and risk factors
35
36
37 11 of functional decline during hospitalization, and its relationship with post-discharge outcomes
38
39
40
41 12 in patients with ADHF hospitalization were as follows; 1) Functional decline during ADHF
42
43
44 13 hospitalization occurred in 15% of patients, and 80% of those with functional decline were
45
46
47 14 ambulatory before admission; 2) The independent baseline risk factors associated with
48
49
50
51 15 functional decline included age ≥ 80 years, women, prior stroke, dementia, elevated body
52
53
54 16 temperature, hyponatremia, decreased albumin levels, eGFR <30 ml/min/1.73m², and NYHA
55
56
57 17 class III or IV; 3) Functional decline during the index hospitalization was associated with
58
59
60

1 higher long-term risk for a composite of all-cause death or heart failure hospitalization.

2
3
4
5
6
7
8 2 This is the first large-scale contemporary multicentre study reporting the
9
10
11 3 prevalence of functional decline in patients hospitalized for ADHF. Of note, we identified the
12
13
14 4 severity of symptoms or patient status specific for heart failure was associated with functional
15
16
17
18 5 decline independent of well-known factors in acute medical illness [18–20]. Functional
19
20
21 6 decline is an inevitable consequence in aged people, but hospitalization accelerates the
22
23
24 7 decline [20–22]. Functional declines have been found to be related not only to impairment of
25
26
27
28 8 independence and quality of life (QOL), but also to increased health service use, higher risk
29
30
31 9 for institutionalization, and higher risk for mortality [23–27]. Indeed, in the present study, the
32
33
34 10 proportion of patients discharged to home was lower in the functional decline group than in
35
36
37
38 11 the no functional decline group, suggesting impaired QOL after discharge. Also, the long-
39
40
41 12 term mortality was worse in the functional decline group than in the no functional decline
42
43
44 13 group. Therefore, it is important to recognize risk factors of functional decline. In previous
45
46
47
48 14 studies of hospitalized patients with acute medical illness, the predictors of functional decline
49
50
51 15 in hospitalized elderly patients were older age, admission diagnosis, lower functional status,
52
53
54 16 impaired cognitive status, comorbidities, and length of hospital stay.[18–20] These findings
55
56
57
58 17 were confirmed in the setting of ADHF in our present study. In addition, findings specific for
59
60

1
2
3
4 1 ADHF such as the dyspnoea or hyponatremia was associated with functional decline, which
5
6
7
8 2 were also reported to be the risk factors for in-hospital mortality in ADHF [28]. The
9
10
11 3 prevalence of oedema and general malaise at discharge was higher in the functional decline
12
13
14 4 group. Early achievement of successful ADHF treatment might reduce the risk of functional
15
16
17 5 decline, although the present observational study could not address the cause-effect
18
19
20
21 6 relationship between the functional decline and the symptomatic status at discharge.
22
23

24 7 There might be several possible strategies to prevent functional decline during
25
26
27 8 ADHF hospitalization. The first is the early improvement of hemodynamic status to avoid
28
29
30
31 9 worsening heart failure. The prevalence of worsening heart failure was higher in the
32
33
34 10 functional decline group. As functional decline associated with hospitalization begins within
35
36
37
38 11 48 hours of admission, early improvement of heart failure to reduce the incidence of
39
40
41 12 hospitalization-associated disability is one of the main goals of care.[28] Second, it would be
42
43
44 13 important to be adequately aware high-risk patients to make aggressive intervention for
45
46
47
48 14 preventing functional decline. We identified the risk factors among the baseline
49
50
51 15 characteristics in ADHF patients. In addition, the adverse events during hospitalization may
52
53
54 16 be tightly related to the functional decline. Stroke is one of causes of functional decline and
55
56
57
58 17 observed in 5.1% of patients with functional decline. Third, a strategy for the prevention of
59
60

1
2
3
4 1 functional decline might be the seamless rehabilitation and comprehensive geriatric
5
6
7
8 2 management through a multidisciplinary team approach.[29–32] In addition, the subgroup
9
10
11 3 analysis showed that there were no interactions between those subgroup factors and the
12
13
14 4 association of functional decline with the primary outcome measure. Thus, prevention of
15
16
17 5 functional decline would have an impact on improving outcomes in all of the patients with
18
19
20
21 6 ADHF. One possible strategy could be immediate, tailored physical function rehabilitation
22
23
24 7 during and after heart failure hospitalization.[33]

8 **Limitations**

9 This study has several limitations. First, we adopted simple classification of
10 functional status as ambulatory, use of wheelchair outdoor only, use of wheelchair indoor and
11 outdoor, and bedridden state based on the definition of Japanese long-term care insurance.
12 The categorization scheme is an easy to understand but coarse measure with very large
13 gradations inherent in each single stage and therefore very likely substantially underestimated
14 the prevalence of meaningful functional decline. Second, we did not collect data regarding
15 on-site and outpatient rehabilitation and nutritional support. However, a team-based approach
16 for heart failure patients was adapted in all the participating centres in the present study.
17 Third, we did not include the status at discharge or adverse in-hospital events in the analysis

1 for the risk factor for functional decline, because the cause-effect relationship was not clear.

2 Fourth, data on post-discharge medication and change of functional status after discharge

3 from the index hospitalization were not collected, and not analysed in the analysis for the

4 long-term outcomes. Fifth, as with any observational study, the possibility of selection bias

5 and residual confounding cannot be excluded, although we adjusted for 29 variables as most

6 conceivable confounders.

7 **Conclusions**

8 Independent risk factors of functional decline in ADHF patients were related to

9 both frailty and severity of heart failure. Functional decline during ADHF hospitalization was

10 associated with unfavourable post-discharge outcomes.

1 **Acknowledgment**

2 We gratefully acknowledge the contributions from KCHF study investigators (Hidenori
3 Yaku, MD; Takao Kato, MD; Neiko Ozasa, MD; Erika Yamamoto, MD; Yusuke Yoshikawa,
4 MD; Tetsuo Shioi, MD; Koichiro Kuwahara, MD; Takeshi Kimura, MD, at Kyoto University
5 Hospital, Kyoto, Japan, Moritake Iguchi, MD; Yugo Yamashita, MD, Masaharu Akao, MD,
6 at National Hospital Organization Kyoto Medical Centre, Kyoto, Japan, Masashi Kato, MD;
7 Shinji Miki, MD, at Mitsubishi Kyoto Hospital, Kyoto, Japan, Mamoru Takahashi, MD, at
8 Shimabara Hospital, Kyoto, Japan, Tsuneaki Kawashima, MD; Takafumi Yagi, MD, at
9 Okamoto Memorial Hospital, Toshikazu Jinnai, MD; Takashi Konishi, MD, at Japanese Red
10 Cross Otsu Hospital, Otsu, Japan, Yasutaka Inuzuka, MD; Shigeru Ikeguchi, MD, at Shiga
11 General Hospital, Moriyama, Japan, Tomoyuki Ikeda, MD; Yoshihiro Himura, MD, at
12 Hikone Municipal Hospital, Hikone, Japan, Kazuya Nagao, MD; Tsukasa Inada, MD, at
13 Osaka Red Cross Hospital, Osaka, Japan, Kenichi Sasaki, MD; Moriaki Inoko, MD, at Kitano
14 Hospital, Osaka, Japan, Takafumi Kawai, MD; Tomoki Sasa, MD; Mitsuo Matsuda, MD, at
15 Kishiwada City Hospital, Kishiwada, Japan, Akihiro Komasa, MD; Katsuhisa Ishii, MD, at
16 Kansai Electric Power Hospital, Osaka, Japan, Yodo Tamaki, MD; Yoshihisa Nakagawa,
17 MD, at Tenri Hospital, Tenri, Japan, Ryoji Taniguchi, MD; Yukihito Sato, MD; Yoshiki

1 Takatsu, MD, at Hyogo Prefectural Amagasaki General Medical Centre, Amagasaki, Japan,
2
3
4
5
6
7
8 2 Takeshi Kitai, MD;, Ryouyusuke Murai, MD; Yutaka Furukawa, MD, at Kobe City Medical
9
10
11 3 Centre General Hospital, Kobe, Japan, Mitsunori Kawato, MD, at Kobe City Nishi-Kobe
12
13
14 4 Medical Centre, Kobe, Japan, Yasuyo Motohashi, MD; Kanae Su, MD; Mamoru Toyofuku,
15
16
17 5 MD; Takashi Tamura, MD, at Japanese Red Cross Wakayama Medical Centre, Wakayama,
18
19
20
21 6 Japan, Reiko Hozo, MD; Ryusuke Nishikawa, MD; Hiroki Sakamoto, MD, at Shizuoka
22
23
24 7 General Hospital, Shizuoka, Japan, Yuichi Kawase, MD; Keiichiro Iwasaki, MD; Kazushige
25
26
27 8 Kadota, MD, at Kurashiki Central Hospital, Kurashiki, Japan, and Takashi Morinaga, MD;
28
29
30
31 9 Yohei Kobayashi, MD; Kenji Ando, MD, at Kokura Memorial Hospital, Kokura, Japan.).
32
33

34 **Sources of Funding**

35
36
37 11 This study is supported by a grant from the Japan Agency for Medical Research and
38
39
40
41 12 Development (18059186) to TK, KK, NO. The founder had no role in the study design,
42
43
44 13 collection, analysis or interpretation of the data, writing the manuscript, or the decision to
45
46
47 14 submit the paper for publication.
48
49

50 51 **Disclosures**

52
53
54 16 None
55

56 57 **Author Contributions**

- 1
2
3
4 1 Drs Yaku and T. Kato had full access to all of the data in the study and take responsibility for
5
6
7
8 2 the integrity of the data and the accuracy of the data analysis.
9
10
11 3 Concept and design: Yaku, T. Kato, Morimoto, Tamaki, Ozasa, Yamamoto, Kitai, M. Kato,
12
13
14 4 Kimura.
15
16
17 5 Acquisition, analysis, or interpretation of data: Yaku, T. Kato, Morimoto, Inuzuka, Tamaki,
18
19
20 6 Yoshikawa, Ikeda, Furukawa, Kuwahara.
21
22
23
24 7 Drafting of the manuscript: Yaku, T. Kato, Kimura.
25
26
27 8 Critical revision of the manuscript for important intellectual content: Yaku, T. Kato,
28
29
30 9 Morimoto, Inuzuka, Tamaki, Yamamoto, Yoshikawa, Kitai, Kuwahara, Kimura.
31
32
33
34 10 Statistical analysis: Yaku, T. Kato, Morimoto.
35
36
37 11 Administrative, technical, or material support: T. Kato, Sato, Kimura.
38
39
40
41 12 Supervision: Inuzuka, Ozasa, Kitai, Furukawa, Nakagawa, Sato, Kuwahara, Kimura.
42
43
44 13 **Ethics approval**
45
46
47 14 The study was approved by the Institutional Review Boards of Kyoto University Graduate
48
49
50 15 School of Medicine (approval number: E2311), Shiga General Hospital (approval number:
51
52
53 16 20141120-01), Tenri Hospital (approval number: 640), Kobe City Medical Centre General
54
55
56 17 Hospital (approval number: 14094), Hyogo Prefectural Amagasaki General Medical Centre
57
58
59
60

1 (approval number: Rinri 26-32), National Hospital Organization Kyoto Medical Centre
2
3
4
5
6
7
8 2 (approval number:14-080), Mitsubishi Kyoto Hospital (approved 11/12/2014), Okamoto
9
10
11 3 Memorial Hospital (approval number: 201503), Japanese Red Cross Otsu Hospital (approval
12
13
14 4 number: 318), Hikone Municipal Hospital (approval number: 26-17), Japanese Red Cross
15
16
17 5 Osaka Hospital (approval number: 392), Shimabara Hospital (approval number: E2311),
18
19
20
21 6 Kishiwada City Hospital (approval number:12), Kansai Electric Power Hospital (approval
22
23
24 7 number: 26-59), Shizuoka General Hospital (approval number: Rin14-11-47), Kurashiki
25
26
27 8 Central Hospital (approval number: 1719), Kokura Memorial Hospital (approval number:
28
29
30
31 9 14111202), Kitano Hospital (approval number: P14-11-012), and Japanese Red Cross
32
33
34 10 Wakayama Medical Centre (approval number: 328).
35
36

37 **Data sharing**

38
39
40
41 12 All data relevant to the study are included in the article or uploaded as supplementary
42
43
44 13 information. No additional data available.
45
46
47
48 14

1
2
3
4 **1 References**
5
6
7

- 8 2 1 Manton KG. A longitudinal study of functional change and mortality in the United
9
10 States. *J Gerontol* 1988;**43**:S153-61.<http://www.ncbi.nlm.nih.gov/pubmed/2971088>
11 3
12
13
14 4 2 Boyd CM, Ricks M, Fried LP, *et al.* Functional decline and recovery of activities of
15
16 daily living in hospitalized, disabled older women: the Women's Health and Aging
17 5
18 Study I. *J Am Geriatr Soc* 2009;**57**:1757–66. doi:10.1111/j.1532-5415.2009.02455.x
19 6
20
21
22
23
24 7 3 Guralnik JM, Alexih L, Branch LG. Medical and Long-Term Care Costs When Older
25
26 Persons Become More Dependent Intentional Weight Loss and 13-Year Diabetes
27 8
28 Incidence in Overweight Adults. *Am J Public Health* 2002;**92**:1244–5.
29 9
30
31
32
33
34 10 4 Gill TM, Allore HG, Holford TR, *et al.* Hospitalization, restricted activity, and the
35
36 development of disability among older persons. *J Am Med Assoc* 2004;**292**:2115–24.
37 11
38
39
40
41 12
42
43
44 13 5 Sager MA, Franke T, Inouye SK, *et al.* Functional outcomes of acute medical illness
45
46 and hospitalization in older persons. *Arch Intern Med* 1996;**156**:645–
47 14
48
49
50
51 15
52
53
54 16 6 Ministry of Education, Culture, Sports, Science and Technology Ministry of Health L
55
56 and W. Japan's ethical guidelines for epidemiologic research.
57 17
58
59
60

- 1
2
3
4 1 2002.http://www.lifescience.mext.go.jp/files/pdf/n796_01.pdf
5
6
7
8 2 7 45 Code of Federal Regulations 46.116(d). 2009;:4–
9
10
11 3 [5.https://www.hhs.gov/ohrp/regulations-and-policy/regulations/45-cfr-](https://www.hhs.gov/ohrp/regulations-and-policy/regulations/45-cfr-)
12
13
14 4 [46/index.html#46.116](https://www.hhs.gov/ohrp/regulations-and-policy/regulations/45-cfr-46/index.html#46.116)
15
16
17 5 8 Yamamoto E, Kato T, Ozasa N, *et al.* Kyoto Congestive Heart Failure (KCHF) study:
18
19
20
21 6 rationale and design. *ESC Hear Fail* 2017;**4**:216–23. doi:10.1002/ehf2.12138
22
23
24 7 9 Yaku H, Ozasa N, Morimoto T, *et al.* Demographics, Management, and In-Hospital
25
26
27
28 8 Outcome of Hospitalized Acute Heart Failure Syndrome Patients in Contemporary
29
30
31 9 Real Clinical Practice in Japan - Observations From the Prospective, Multicenter
32
33
34 10 Kyoto Congestive Heart Failure (KCHF) Registry. *Circ J* 2018;**82**:2811–9.
35
36
37 11 doi:10.1253/circj.CJ-17-1386
38
39
40
41 12 10 Yaku H, Kato T, Morimoto T, *et al.* Association of Mineralocorticoid Receptor
42
43
44 13 Antagonist Use with All-Cause Mortality and Hospital Readmission in Older Adults
45
46
47
48 14 with Acute Decompensated Heart Failure. *JAMA Netw Open* 2019;**2**:1–14.
49
50
51 15 doi:10.1001/jamanetworkopen.2019.5892
52
53
54 16 11 Su K, Kato T, Toyofuku M, *et al.* Association of Previous Hospitalization for Heart
55
56
57
58 17 Failure With Increased Mortality in Patients Hospitalized for Acute Decompensated
59
60

- 1
2
3
4 1 Heart Failure. *Circ Reports* 2019;**1**:517–24. doi:10.1253/circrep.CR-19-0054
5
6
7
8 2 12 Butler J, Gheorghiade M, Kelkar A, *et al.* In-hospital worsening heart failure. *Eur J*
9
10
11 3 *Heart Fail* 2015;**17**:1104–13. doi:10.1002/ejhf.333
12
13
14 4 13 Filippatos G, Farmakis D, Parissis J. Renal dysfunction and heart failure: Things are
15
16
17 5 seldom what they seem. *Eur Heart J* 2014;**35**:416–8. doi:10.1093/eurheartj/ehf515
18
19
20
21 6 14 Vardeny O, Wu DH, Desai A, *et al.* Influence of baseline and worsening renal function
22
23
24 7 on efficacy of spironolactone in patients with severe heart failure: Insights from rales
25
26
27 8 (randomized aldactone evaluation study). *J Am Coll Cardiol* 2012;**60**:2082–9.
28
29
30 9 doi:10.1016/j.jacc.2012.07.048
31
32
33
34 10 15 Clark H, Krum H, Hopper I. Worsening renal function during renin-angiotensin-
35
36
37 11 aldosterone system inhibitor initiation and long-term outcomes in patients with left
38
39
40
41 12 ventricular systolic dysfunction. *Eur J Heart Fail* 2014;**16**:41–
42
43
44 13 8.[http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L3](http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L372684240%5Cnhttp://dx.doi.org/10.1002/ejhf.13)
45
46
47 14 [72684240%5Cnhttp://dx.doi.org/10.1002/ejhf.13](http://dx.doi.org/10.1002/ejhf.13)
48
49
50
51 15 16 Ponikowski P, Voors AA, Anker SD, *et al.* 2016 ESC Guidelines for the diagnosis and
52
53
54 16 treatment of acute and chronic heart failure: The Task Force for the diagnosis and
55
56
57 17 treatment of acute and chronic heart failure of the European Society of Cardiology
58
59
60

- 1
2
3
4 1 (ESC). Developed with the special contribution . *Eur J Heart Fail* 2016;**18**:891–975.
5
6
7
8 2 doi:10.1002/ejhf.592
9
10
11 3 17 Oda E, Oohara K, Abe A, *et al*. The optimal cut-off point of C-reactive protein as an
12
13
14 4 optional component of metabolic syndrome in Japan. *Circ J* 2006;**70**:384–8.
15
16
17 5 doi:10.1253/circj.70.384
18
19
20
21 6 18 Stuck AE, Walthert JM, Nikolaus T, *et al*. Risk factors for functional status decline in
22
23
24 7 community-living elderly people: a systematic literature review. *Soc Sci Med*
25
26
27 8 1999;**48**:445–69. doi:10.1016/S0277-9536(98)00370-0
28
29
30
31 9 19 McCusker J, Kakuma R, Abrahamowicz M. Predictors of functional decline in
32
33
34 10 hospitalized elderly patients: a systematic review. *J Gerontol A Biol Sci Med Sci*
35
36
37 11 2002;**57**:M569-77.<http://www.ncbi.nlm.nih.gov/pubmed/12196493>
38
39
40
41 12 20 Covinsky KE, Palmer RM, Fortinsky RH, *et al*. Loss of independence in activities of
42
43
44 13 daily living in older adults hospitalized with medical illnesses: increased vulnerability
45
46
47 14 with age. *J Am Geriatr Soc* 2003;**51**:451–
48
49
50
51 15 8.<http://www.ncbi.nlm.nih.gov/pubmed/12657063>
52
53
54 16 21 Inouye SK, Bogardus ST, Baker DI, *et al*. The hospital elder life program: A model of
55
56
57 17 care to prevent cognitive and functional decline in older hospitalized patients. *J Am*
58
59
60

- 1
2
3
4 1 *Geriatr Soc* 2000;**48**:1697–706. doi:10.1111/j.1532-5415.2000.tb03885.x
- 5
6
7 2 22 Pandharipande PP, Girard TD, Jackson JC, *et al.* Long-term cognitive impairment after
8
9
10
11 3 critical illness. *N Engl J Med* 2013;**369**:1306–16. doi:10.1056/NEJMoa1301372
12
13
14 4 23 Hirvensalo M, Rantanen T, Heikkinen E. Mobility difficulties and physical activity as
15
16
17 5 predictors of mortality and loss of independence in the community-living older
18
19
20
21 6 population. *J Am Geriatr Soc* 2000;**48**:493–8. doi:10.1111/j.1532-
22
23
24 7 5415.2000.tb04994.x
25
26
27 8 24 Greiner PA, Snowdon DA, Schmitt FA. The loss of independence in activities of daily
28
29
30 9 living: The role of low normal cognitive function in elderly nuns. *Am J Public Health*
31
32
33
34 10 1996;**86**:62–6. doi:10.2105/AJPH.86.1.62
35
36
37 11 25 Ganguli M, MPH ES, PhD SB, *et al.* Cognitive Impairment and the Use of Health
38
39
40
41 12 Services in an Elderly Rural Population: The MoVIES Project. *J Am Geriatr Soc*
42
43
44 13 1993;**41**:1065–70. doi:10.1111/j.1532-5415.1993.tb06453.x
45
46
47 14 26 Barberger-Gateau P, Fabrigoule C. Disability and cognitive impairment in the elderly.
48
49
50
51 15 *Disabil Rehabil* 1997;**19**:175–93. <http://www.ncbi.nlm.nih.gov/pubmed/9184783>
52
53
54 16 27 Black SA, Rush RD. Cognitive and functional decline in adults aged 75 and older. *J*
55
56
57 17 *Am Geriatr Soc* 2002;**50**:1978–86. doi:10.1046/j.1532-5415.2002.50609.x
58
59
60

- 1
2
3
4 1 28 Hirsch CH, Sommers L, Olsen A, *et al.* The natural history of functional morbidity in
5
6
7
8 2 hospitalized older patients. *J Am Geriatr Soc* 1990;**38**:1296–
9
10
11 3 303.<http://www.ncbi.nlm.nih.gov/pubmed/2123911>
12
13
14 4 29 O'Connor CM, Whellan DJ, Lee KL, *et al.* Efficacy and safety of exercise training in
15
16
17 5 patients with chronic heart failure: HF-ACTION randomized controlled trial. *JAMA*
18
19
20
21 6 2009;**301**:1439–50. doi:10.1001/jama.2009.454
22
23
24 7 30 Baztán JJ, Suárez-García FM, López-Arrieta J, *et al.* Effectiveness of acute geriatric
25
26
27 8 units on functional decline, living at home, and case fatality among older patients
28
29
30
31 9 admitted to hospital for acute medical disorders: Meta-analysis. *BMJ* 2009;**338**:334–6.
32
33
34 10 doi:10.1136/bmj.b50
35
36
37 11 31 Fox MT, Persaud M, Maimets I, *et al.* Effectiveness of acute geriatric unit care using
38
39
40
41 12 acute care for elders components: A systematic review and meta-analysis. *J Am*
42
43
44 13 *Geriatr Soc* 2012;**60**:2237–45. doi:10.1111/jgs.12028
45
46
47
48 14 32 Bachmann S, Finger C, Huss A, *et al.* Inpatient rehabilitation specifically designed for
49
50
51 15 geriatric patients: Systematic review and meta-analysis of randomised controlled trials.
52
53
54 16 *BMJ* 2010;**340**:1230. doi:10.1136/bmj.c1718
55
56
57 17 33 Reeves GR, Whellan DJ, Duncan P, *et al.* Rehabilitation Therapy in Older Acute Heart
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 Failure Patients (REHAB-HF) trial: Design and rationale. *Am Heart J* 2017;**185**:130–

2 9. doi:10.1016/j.ahj.2016.12.012

3

4

For peer review only

1
2
3
4 **1 Figure legends**
5

6
7
8 **2 Figure 1. Patient flowchart.** KCHF=Kyoto Congestive Heart Failure, ADHF=acute
9
10
11 decompensated heart failure.
12

13
14 **4 Figure 2. Clinical factors associated with functional decline during hospitalization in the**
15
16
17 **5 univariate and multivariable logistic regression models.** BMI=body mass index, LVEF=left
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
6
7
8
9
10
11
12
ventricular ejection, HF=heart failure, eGFR=estimated glomerular filtration rate, BP=blood
pressure, NYHA=New York Heart Association, OR=odds ratio, CI=confidence interval.

8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
8
9
10
11
12
**8 Figure 3. The Cumulative incidences for the primary outcome measure (A), for all-
9 cause death (B), for HF hospitalization (C), and for a composite of all-cause death or all-
10 cause hospitalization (D) according to the presence or absence of functional decline.**
11
12
HF=heart failure, HR=hazard ratio, CI=confidence interval.

Table 1. Patient Characteristics

	Functional decline	No functional decline	P value
	N=528	N=3027	
Clinical characteristics			
Age, years	85 [80–89]	79 [70–85]	<0.001
Age ≥80 years*†	399 (76)	1407 (46)	<0.001
Women*†	294 (56)	1278 (42)	<0.001
BMI, kg/m ²	22.0±4.0	23.1±4.5	<0.001
BMI ≤22 kg/m ² *†	269 (55)	1281 (44)	<0.001
Medical history			
Prior heart failure hospitalization*†	186 (36)	1077 (36)	0.92
Atrial fibrillation or flutter	220 (42)	1263 (42)	0.98
Hypertension*†	406 (77)	2174 (72)	0.02
Diabetes mellitus*†	187 (35)	1145 (38)	0.29
Prior myocardial infarction*†	112 (21)	681 (23)	0.51
Prior stroke*†	125 (24)	432 (14)	<0.001
Current smoking*†	28 (5.5)	425 (14)	<0.001
Malignancy	97 (18)	419 (14)	0.006
Chronic lung disease*†	41 (7.8)	247 (8.2)	0.76
Dementia*†	175 (33)	423 (14)	<0.001
Social backgrounds at admission			
Poor medical adherence	100 (19)	498 (16)	0.16
Living alone*†	127 (24)	652 (22)	0.20
Public assistance	24 (4.6)	186 (6.1)	0.14
Functional status before admission			
Ambulatory	420 (80)	2529 (84)	0.02
Use of wheelchair [outdoor only]	80 (15)	192 (6.3)	<0.001
Use of wheelchair [outdoor and indoor]	28 (5.3)	306 (10)	<.0001
Origin			
Ischemic	134 (25)	820 (27)	0.41
Acute coronary syndrome*†	36 (6.8)	166 (5.5)	0.22
Hypertensive	131 (25)	754 (25)	0.96

1				
2				
3	Valvular	124 (23)	565 (19)	<0.001
4	Cardiomyopathy	54 (10)	492 (16)	<0.001
5				
6				
7	Vital signs and symptoms at presentation			
8	BP, mmHg			
9				
10	Systolic BP	144±32	149±35	0.003
11				
12	Systolic BP ≥140 mmHg	275 (53)	1741 (58)	0.03
13				
14	Systolic BP <90 mmHg*†	12 (2.3)	76 (2.5)	0.76
15	Diastolic BP	81±23	86±24	<0.001
16				
17	Heart rate, beat/min	93±27	96±28	0.001
18				
19	Heart rate <60 beat/min*†	44 (8.5)	195 (6.5)	0.11
20	Body temperature, °C	36.6±0.7	36.5±0.6	<0.001
21				
22	Body temperature ≥37.5°C*†	58 (11)	154 (5.3)	<0.001
23				
24	Rhythms at presentation			
25	Sinus rhythm	280 (53)	1715 (57)	0.12
26				
27	Atrial fibrillation or flutter*†	198 (38)	1085 (36)	0.47
28				
29	NYHA class III or IV*†	482 (92)	2598 (73)	<0.001
30	Tests at admission			
31				
32	LVEF	48±16	46±16	0.02
33				
34	HFrEF (EF<40%)*†	167 (32)	1148 (38)	0.006
35				
36	HFmrEF (EF 40–49%)	117 (22)	566 (19)	0.06
37				
38	HFpEF (EF ≥50%)	242 (46)	1305 (43)	0.24
39	Haemoglobin, g/dL	11.0±2.1	11.7±2.4	<0.001
40				
41	Anaemia*†‡	401 (76)	1946 (64)	<0.001
42	BNP, pg/ml	782 [448–1410]	687 [375–1214]	<0.001
43				
44	NT-proBNP, pg/ml	10795 [3450–	5416 [2629–	0.001
45		18000]	11438]	
46				
47	Creatinine, mg/dL	1.2 [0.8–1.6]	1.1 [0.8–1.6]	0.21
48				
49	eGFR, ml/min/1.73m ²	38 [24–54]	46 [30–62]	<0.001
50				
51	eGFR <30 ml/min/1.73m ² *†	195 (37)	747 (25)	<0.001
52	Blood urea nitrogen, mg/dL	28 (20–39)	23 (17–33)	<0.001
53				
54	Albumin, g/dL	3.3±0.5	3.5±0.5	<0.001
55				
56	Albumin <3.0 g/dL*†	112 (22)	332 (11)	<0.001
57	Sodium, mEq/L	138±4.7	139±4.1	<0.001
58				
59	Sodium <135 mEq/L*†	83 (16)	325 (11)	0.001
60				

Potassium, mEq/L	4.3±0.8	4.2±0.6	0.03
Clinical signs and symptoms at discharge			
Oedema†	89 (17)	320 (11)	<0.001
General malaise†	152 (31)	388 (14)	<0.001
Medications at discharge			
Number of drugs prescribed	8 (6–11)	9 (6–11)	0.12
Loop diuretics†	428 (81)	2472 (82)	0.74
ACEI or ARB†	242 (46)	1838 (61)	<0.001
MRA†	208 (39)	1409 (47)	0.002
Beta blocker†	287 (54)	2101 (69)	<0.001
Tolvaptan	76 (14)	299 (9.9)	0.002
Functional status at discharge			
Ambulatory	0	2682 (89)	<0.001
Use of wheelchair [outdoor only]	184 (35)	160 (5.3)	<0.001
Use of wheelchair [outdoor and indoor]	261 (49)	185 (6.1)	<.0001
Bedridden	83 (16)	0	<0.001
Living place after discharge			
Home	247 (47)	2709 (90)	<0.001
Hospital	225 (43)	180 (6.0)	<0.001
Institution for the aged	50 (9.5)	114 (3.8)	<0.001
Other	4 (0.8)	17 (0.6)	0.59

Abbreviations: BMI, body mass index; BP, blood pressure; NYHA, New York Heart Association; LVEF, left ventricular ejection fraction; HFrEF, heart failure with reduced ejection fraction; HFmrEF, heart failure with mid-range ejection fraction; HFpEF, heart failure with preserved ejection fraction; BNP, brain-type natriuretic peptide; NT-proBNP, N-terminal-proBNP; eGFR, estimated glomerular filtration rate; ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; MRA, mineralocorticoid receptor antagonist.

Continuous variables were presented as mean ± SD or median with [interquartile range]. Categorical variables were presented as number (percentage).

* Risk-adjusting variables were selected for multivariable logistic regression models.

† Risk-adjusting variables were selected for multivariable Cox proportional hazard models.

‡ Defined by the World Health Organization criteria (haemoglobin <12 g/dL for women and <13 g/dL for men).

Table 2. In-hospital Management and Outcome

	Functional decline	No functional decline	P value
	N=528	N=3027	
In-hospital management			
Management in the emergency room			
Respiratory management			
Oxygen inhalation	295 (56)	1382 (46)	<0.001
NIPPV	82 (16)	423 (14)	0.35
Intubation	11 (2.1)	53 (1.8)	0.60
Intravenous drugs within 24 hours after hospital presentation			
Inotropes	101 (19)	405 (13)	<0.001
Furosemide	446 (85)	2536 (84)	0.69
In-hospital clinical outcomes			
In-hospital adverse events			
Stroke	27 (5.1)	26 (0.9)	<0.001
Worsening heart failure	130 (25)	490 (16)	<0.001
Worsening renal function	244 (47)	992 (33)	<0.001
In-hospital infection	104 (20)	258 (8.5)	<0.001
Length of stay, day	21 [14–37]	15 [11–22]	<0.001

Abbreviations: NIPPV, non-invasive intermittent positive pressure ventilation.

1

KCHF registry
4056 patients hospitalized with ADHF
 (Oct 2014-Mar 2016, 19 centers in Japan)

In-hospital death during index hospitalization (N=271)

Excluded (N=230)
 No data about functional status (n = 99)
 Bedridden before index hospitalization (n = 131)

Study population:
Patients discharged alive assessed for functional decline during hospitalization
3555 patients

Functional decline: 528 patients

No functional decline: 3027 patients

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31

Variables	Unadjusted OR (95%CI)	P Value	Adjusted OR (95%CI)	P Value
Age ≥80 years	3.56 (2.88–4.40)	<0.001	2.56 (1.98–3.32)	<0.001
1 Women	1.72 (1.43–2.07)	<0.001	1.27 (1.01–1.60)	0.04
2 BMI ≤22	1.59 (1.31–1.93)	<0.001	1.20 (0.96–1.50)	0.11
4 LVEF <40%	0.76 (0.62–0.92)	0.006	1.14 (0.89–1.45)	0.29
5 Prior HF hospitalization	0.99 (0.82–1.20)	0.92	0.82 (0.65–1.04)	0.10
7 Acute coronary syndrome	1.26 (0.87–1.83)	0.22	1.53 (0.97–2.43)	0.07
8 Hypertension	1.31 (1.05–1.62)	0.02	1.11 (0.85–1.44)	0.46
10 Diabetes mellitus	0.90 (0.74–1.09)	0.29	1.03 (0.81–1.31)	0.81
11 Atrial fibrillation or flutter	1.00 (0.83–1.20)	0.98	1.02 (0.81–1.29)	0.85
12 Prior myocardial infarction	0.93 (0.74–1.16)	0.51	0.90 (0.69–1.19)	0.47
14 Prior stroke	1.86 (1.49–2.33)	<0.001	1.61 (1.23–2.10)	<0.001
15 Chronic lung disease	1.07 (0.82–1.40)	0.61	1.14 (0.83–1.56)	0.41
17 Cognitive dysfunction	3.05 (2.48–3.76)	<0.001	1.95 (1.52–2.52)	<0.001
18 Current smoking	0.35 (0.23–0.51)	<0.001	0.56 (0.36–0.88)	0.01
20 Living alone	1.15 (0.93–1.43)	0.20	1.20 (0.93–1.56)	0.17
21 Anemia	1.74 (1.1–2.16)	<0.001	1.10 (0.84–1.44)	0.48
23 Albumin <3.0 g/dL	2.16 (1.71–2.75)	<0.001	1.69 (1.27–2.24)	<0.001
24 Sodium <135 mEq/L	1.55 (1.19–2.01)	0.001	1.46 (1.07–1.98)	0.02
25 eGFR <30 ml/min/1.73m ²	1.79 (1.47–2.18)	<0.001	1.54 (1.21–1.96)	<0.001
27 Systolic BP <90 mmHg	0.91 (0.49–1.68)	0.76	0.61 (0.26–1.43)	0.25
29 Heart rate <60 beat/min	1.33 (0.95–1.87)	0.10	1.12 (0.75–1.69)	0.57
30 Body temperature ≥37.5 °C	2.30 (1.67–3.16)	<0.001	1.88 (1.29–2.74)	<0.001
32 NYHA III/IV on admission	1.81 (1.30–2.52)	<0.001	1.51 (1.05–2.18)	0.03



Odds ratio (95%CI)

Odds ratio (95%CI)

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>

Figure 3A




Figure 3B




Figure 3C




Figure 3D




Figure 3. The Cumulative incidences for the primary outcome measure (A), for all-cause death (B), for HF hospitalization (C), and for a composite of all-cause death or all-cause hospitalization (D) according to the presence or absence of functional decline.

99x149mm (300 x 300 DPI)

Supplementary Online Content

eTable 1. Number of missing values in the entire cohort

eTable 2. Clinical factors associated with functional decline in the entire cohort in the univariate and multivariable Analyses

eTable 3. Clinical outcomes in the entire cohort

eFigure 1. The details of functional decline during ADHF Hospitalization.

eFigure 2. Subgroup analysis for the association of functional decline with no functional decline on the primary outcome measure.

For peer review only

eTable 1. Number of missing values in the entire cohort

	Entire Cohort (N=3555)	
	Number	Rate (%)
Tests at admission		
BNP or NT-proBNP *	46	1.24
Serum creatinine	6	0.16
eGFR	6	0.16
Blood urea nitrogen	11	0.30
Albumin	110	2.96
Sodium	13	0.35
Potassium	13	0.35
Haemoglobin	6	0.16

* BNP values were reported for 1887 patients in the matched cohort and 3394 patients in the entire cohort; NT-proBNP values were reported for 181 patients in the matched cohort and 323 patients in the entire cohort.
Abbreviation: BNP, brain-type natriuretic peptide; NT-proBNP, N-terminal-proBNP; eGFR, estimated glomerular filtration rate.

Table 2. Clinical factors associated with functional decline in the entire cohort in the univariate and multivariable analyses

Variables	Unadjusted OR (95% CI)	P Value	Adjusted OR (95% CI)	P Value
Age ≥80 years	2.97 (2.50–3.52)	<0.001	2.25 (1.81–2.81)	<0.001
Women	1.45 (1.25–1.70)	<0.001	1.10 (0.90–1.34)	0.37
BMI ≤22	1.56 (1.32–1.83)	<0.001	1.19 (0.98–1.45)	0.08
LVEF <40%	1.04 (0.89–1.22)	0.61	1.23 (1.00–1.52)	0.048
Prior HF hospitalization	1.08 (0.92–1.27)	0.36	0.97 (0.79–1.19)	0.80
Acute coronary syndrome	1.56 (1.16–2.11)	0.003	1.73 (1.17–2.56)	0.006
Hypertension	1.00 (0.85–1.20)	0.95	0.97 (0.77–1.21)	0.76
Diabetes mellitus	0.86 (0.73–1.01)	0.06	0.88 (0.71–1.08)	0.22
Atrial fibrillation or flutter	0.97 (0.83–1.13)	0.67	0.91 (0.74–1.11)	0.33
Prior myocardial infarction	0.94 (0.78–1.13)	0.50	0.87 (0.69–1.11)	0.26
Prior stroke	1.73 (1.43–2.10)	<0.001	1.54 (1.21–1.94)	<0.001
Chronic lung disease	1.11 (0.89–1.39)	0.37	1.16 (0.89–1.52)	0.27
Dementia	2.91 (2.44–3.47)	<0.001	2.03 (1.63–2.53)	<0.001
Current smoking	0.37 (0.27–0.51)	<0.001	0.56 (0.38–0.82)	0.003
Living alone	1.05 (0.87–1.27)	0.62	1.19 (0.94–1.49)	0.14
Anaemia*	1.67 (1.39–1.98)	<0.001	1.07 (0.85–1.35)	0.56
Albumin <3.0 g/dL	2.30 (1.89–2.81)	<0.001	1.83 (1.44–2.33)	<0.001
Sodium <135 mEq/L	1.89 (1.53–2.33)	<0.001	1.68 (1.31–2.16)	<0.001
eGFR <30 ml/min/1.73m ²	2.01 (1.70–2.36)	<0.001	1.76 (1.43–2.17)	<0.001
Systolic BP <90 mmHg	2.01 (1.37–2.96)	<0.001	1.17 (0.67–2.05)	0.58
Heart rate <60 beat/min	1.07 (0.79–0.79)	0.66	1.03 (0.72–1.49)	0.87
Body temperature ≥37.5 °C	2.26 (1.72–2.7)	<0.001	1.89 (1.35–2.63)	<0.001
NYHA class III or IV	2.17 (1.62–2.91)	<0.001	1.69 (1.21–2.35)	0.002

*Defined by the World Health Organization criteria (haemoglobin <12 g/dL for women and <13 g/dL for men).

Abbreviations: OR, odds ratio; CI, confidence interval; BMI, body mass index; LVEF, left ventricular ejection; HF, heart failure; eGFR, estimated glomerular filtration rate; BP, blood pressure; NYHA, New York Heart Association.


eTable 3. Clinical outcomes in the entire cohort

Outcomes	Functional decline	No functional decline	Unadjusted HR (95% CI)	P value	Adjusted HR (95% CI)	P value
	N of patients with event / N of patients at risk (Cumulative 1- year incidence [%])	N of patients with event / N of patients at risk (Cumulative 1- year incidence [%])				
All-cause death or HF hospitalization	243/528 (49)	902/3027 (31)	1.95 (1.71–2.21)	<0.001	1.39 (1.18–1.62)	<0.001
All-cause death	174/528 (36)	386/3027 (13)	3.02 (2.58–3.53)	<0.001	1.92 (1.57–2.34)	<0.001
HF hospitalization	116/528 (28)	663/3027 (23)	1.25 (1.04–1.50)	0.02	0.99 (0.80–1.24)	0.97
All-cause death or All- cause hospitalization	279/528 (57)	1186/3027 (40)	1.69 (1.50–1.91)	<0.001	1.34 (1.15–1.55)	<0.001


The number of patients with at least one event was counted through the 1-year follow-up period.

Abbreviations: HF, heart failure; HR, hazard ratio; CI, confidence interval.

eFigure 1. The details of functional decline during ADHF hospitalization. Functional status at discharge according to functional status before admission is shown. ADHF=acute decompensated heart failure.



eFigure 2. Subgroup analysis for the association of functional decline with no functional decline on the primary outcome measure. LVEF=left ventricular ejection fraction, HR=hazard ratio, CI=confidence interval.



STROBE 2007 (v4) Statement—Checklist of items that should be included in reports of *cohort studies*

Section/Topic	Item #	Recommendation	Reported on page #
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	Page 1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	Page 3-4
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	Page 6
Objectives	3	State specific objectives, including any prespecified hypotheses	Page 8
Methods			
Study design	4	Present key elements of study design early in the paper	Page 7
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	Page 7-8
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	Page 8
		(b) For matched studies, give matching criteria and number of exposed and unexposed	
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	Page 8-10
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	Page 8
Bias	9	Describe any efforts to address potential sources of bias	Page 10
Study size	10	Explain how the study size was arrived at	Page 8
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	Page 9
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	Page 9-10
		(b) Describe any methods used to examine subgroups and interactions	Page 10-11
		(c) Explain how missing data were addressed	Page 9
		(d) If applicable, explain how loss to follow-up was addressed	Page
		(e) Describe any sensitivity analyses	Page 11
Results			

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	Page 12
		(b) Give reasons for non-participation at each stage	Page 8
		(c) Consider use of a flow diagram	Page 7-8
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	Page 12
		(b) Indicate number of participants with missing data for each variable of interest	Page 7-8
		(c) Summarise follow-up time (eg, average and total amount)	Page 12
Outcome data	15*	Report numbers of outcome events or summary measures over time	Page 14
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	Page 13-15
		(b) Report category boundaries when continuous variables were categorized	Page 10-11
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	Page 14-15
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	Page 15-16
Discussion			
Key results	18	Summarise key results with reference to study objectives	Page 16
Limitations			
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	Page 19-20
Generalisability	21	Discuss the generalisability (external validity) of the study results	Page 19-20
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	Page 22

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

BMJ Open

Risk factors and clinical outcomes of functional decline during hospitalization in very old patients with acute decompensated heart failure: an observational study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-032674.R2
Article Type:	Original research
Date Submitted by the Author:	02-Dec-2019
Complete List of Authors:	Yaku, Hidenori; Kyoto University Graduate School of Medicine Faculty of Medicine, Department of Cardiovascular Medicine; Mitsubishi Kyoto Hospital, Cardiology Kato, Takao; Kyoto University Graduate School of Medicine Faculty of Medicine, Department of Cardiovascular Medicine Morimoto, Takeshi; Hyogo College of Medicine, Clinical Epidemiology Inuzuka, Yasutaka; Shiga General Hospital, Cardiovascular Medicine Tamaki, Yodo; Public Interest Incorporated Foundation Tenri Hospital, Cardiology Ozasa, Neiko; Kyoto University Graduate School of Medicine Faculty of Medicine, Department of Cardiovascular Medicine Yamamoto, Erika; Kyoto University Graduate School of Medicine Faculty of Medicine, Department of Cardiovascular Medicine Yoshikawa, Yusuke; Kyoto University Graduate School of Medicine Faculty of Medicine, Department of Cardiovascular Medicine Kitai, Takeshi; Kobe City Medical Center General Hospital, Cardiovascular Medicine Kato, Masashi; Mitsubishi Kyoto Hospital, Department of Cardiology Ikeda, Tomoyuki; Hikone Municipal Hospital, Department of Cardiology Furukawa, Yutaka; Kobe City Medical Center General Hospital, Cardiovascular Medicine Nakagawa, Yoshihisa; Shiga University of Medical Science, Cardiovascular Medicine Sato, Yukihiro; Hyogo Prefectural Amagasaki General Medical Center, Cardiology Kuwahara, Koichiro ; Shinshu University Graduate School of Medicine School of Medicine, Cardiovascular Medicine Kimura, Takeshi; Kyoto University Graduate School of Medicine Faculty of Medicine, Department of Cardiovascular Medicine
Primary Subject Heading:	Cardiovascular medicine
Secondary Subject Heading:	Cardiovascular medicine
Keywords:	Heart failure < CARDIOLOGY, Adult cardiology < CARDIOLOGY, Cardiac Epidemiology < CARDIOLOGY

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60





I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3
4 **1 Risk factors and clinical outcomes of functional decline during hospitalization in very**
5
6
7 **2 old patients with acute decompensated heart failure: an observational study**
8
9
10
11 3

12
13 **4 Authors:** Hidenori Yaku, MD ^{a,f}, Takao Kato, MD ^a, Takeshi Morimoto, MD, MPH ^b,
14
15 Yasutaka Inuzuka, MD ^c, Yodo Tamaki, MD ^d, Neiko Ozasa, MD ^a, Erika Yamamoto, MD ^a,
16
17 Yusuke Yoshikawa, MD ^a, Takeshi Kitai, MD ^e, Masashi Kato, MD ^f, Tomoyuki Ikeda
18
19 ^g, Yutaka Furukawa, MD ^e, Yoshihisa Nakagawa, MD ^h, Yukihiro Sato, MD ⁱ, Koichiro
20
21
22 8 Kuwahara, MD ^j, Takeshi Kimura, MD ^a, for the KCHF study investigators
23
24
25 9

26
27
28 **10 Affiliations:** ^a Department of Cardiovascular Medicine, Kyoto University Graduate School of
29
30
31 Medicine, Kyoto, Japan; ^b Department of Clinical Epidemiology, Hyogo College of
32
33
34
35 ¹² Medicine, Hyogo, Japan; ^c Department of Cardiovascular Medicine, Shiga General Hospital,
36
37
38 ¹³ Shiga, Japan; ^d Division of Cardiology, Tenri Hospital, Nara, Japan; ^e Department of
39
40
41 ¹⁴ Cardiovascular Medicine, Kobe City Medical Centre General Hospital, Hyogo, Japan; ^f
42
43
44
45 ¹⁵ Department of Cardiology, Mitsubishi Kyoto Hospital, Kyoto, Japan; ^g Department of
46
47
48 ¹⁶ Cardiology, Hikone Municipal Hospital, Shiga, Japan; ^h Department of Cardiovascular
49
50
51 ¹⁷ Medicine, Shiga University of Medical Science, Shiga, Japan; ⁱ Department of Cardiology,
52
53
54
55 ¹⁸ Hyogo Prefectural Amagasaki General Medical Centre, Hyogo, Japan; ^j Department of
56
57
58 ¹⁹ Cardiovascular Medicine, Shinshu University Graduate School of Medicine, Nagano, Japan.
59
60

1

2 **Corresponding Author:** Takao Kato, MD.

3 Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine

4 54 Shogoin Kawahara-cho, Sakyo-ku, Kyoto. 606-8507 Japan

5 Tel: +81-75-751-4254; FAX: +81-75-751-3289; E-mail: tkato75@kuhp.kyoto-u.ac.jp

6

7 **Manuscript word count:** 2927 words

8

For peer review only

1
2
3
4 **1 Abstract**

5
6
7 **2 Objective:** To investigate the prevalence and risk factors of functional decline during
8
9
10
11 **3** hospitalization, and its relationship with post-discharge outcomes in very old patients with
12
13
14 **4** acute decompensated heart failure (ADHF) hospitalization.

15
16
17 **5 Design:** Prospective cohort study between October 1, 2014, and March 31, 2016.

18
19
20
21 **6 Setting:** A physician-initiated multicentre study of consecutive patients admitted for ADHF
22
23
24 **7** into 19 hospitals throughout Japan.

25
26
27 **8 Participants:** Among 3555 patients hospitalized for ADHF (median age [IQR], 80 [71-86]
28
29
30
31 **9** years; 1572 [44%] women), functional decline during the index hospitalization occurred in
32
33
34 **10** 528 patients (15%).

35
36
37 **11 Primary and secondary outcomes:** The primary outcome measure was a composite of all-
38
39
40
41 **12** cause death or heart failure (HF) hospitalization after discharge. The secondary outcome
42
43
44 **13** measures were all-cause death, HF hospitalization, and a composite of all-cause death or all-
45
46
47 **14** cause hospitalization.

48
49
50
51 **15 Results:** The independent risk factors for functional decline included age ≥ 80 years (OR
52
53
54 **16** 2.71; 95%CI 2.09–3.51), women (OR 1.32; 95%CI 1.05–1.67), prior stroke (OR 1.67; 95%
55
56
57 **17** CI 1.28–2.19), dementia (OR 2.26; 95%CI 1.74–2.95), ambulatory before admission (OR

1 1.74; 95%CI 1.29–2.35), elevated body temperature (OR 1.91; 95%CI 1.31–2.79), New York
2
3
4
5
6
7
8 2 Heart Association class III or IV on admission (OR 1.54; 95%CI 1.07–2.22), decreased
9
10
11 3 albumin levels (OR 1.76; 95%CI 1.32–2.34), hyponatremia (OR 1.49; 95%CI 1.10–2.03),
12
13
14 4 renal dysfunction (OR 1.55; 95%CI 1.22–1.98) after multivariable adjustment. The
15
16
17
18 5 cumulative 1-year incidence of the primary outcome in the functional decline group was
19
20
21 6 significantly higher than that in the no functional decline group (50% vs. 31%, log-rank
22
23
24 7 $P<0.001$). After adjusting for baseline characteristics, the higher risk of the functional decline
25
26
27
28 8 group relative to the no functional decline group remained significant (adjusted HR 1.46;
29
30
31 9 95% CI 1.24–1.71; $P<0.001$).

32
33
34 10 **Conclusions:** Independent risk factors of functional decline in very old patients with ADHF
35
36
37 11 were related to both frailty and severity of HF. Functional decline during ADHF
38
39
40
41 12 hospitalization was associated with unfavourable post-discharge outcomes.

42
43
44 13 **Trial Registration:** <https://clinicaltrials.gov/ct2/show/NCT02334891> (NCT02334891) and
45
46
47
48 14 https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000017241
49
50
51 15 (UMIN000015238)

52
53
54 16

1 Strengths and limitations of this study

- 2 • This study is the first large-scale contemporary multicentre observational study reporting
3 the prevalence of functional decline in very old patients hospitalized for acute
4 decompensated heart failure (ADHF).
- 5 • The data of this study were prospectively collected on consecutive patients who had
6 hospital admission due to ADHF in the real-world clinical practice in Japan.
- 7 • This study examines the risk factors of functional decline in very old patients
8 hospitalized for ADHF, and whether functional decline during the index hospitalization
9 was associated with worse post-discharge outcomes.
- 10 • We did not collect data regarding on-site and outpatient rehabilitation and nutritional
11 support.

1 Introduction

2 Functional decline in hospitalized patients is a complex and dynamic process [1–3].
3 Functional decline during hospitalization was reported to occur in approximately 30-50% of
4 patients hospitalized for acute medical illness [2,4,5]. In the rapidly aging societies, the
5 number of very old patients hospitalized for acute decompensated heart failure (ADHF) is
6 increasing, and ADHF has become the leading cause of hospitalization due to acute medical
7 illness. In older patients, functional decline associated with hospitalization often leads to
8 subsequent inability to live actively and independently.

9 However, there is a scarcity of data regarding the risk factors of functional decline
10 in very old patients hospitalized for ADHF. Identifying high-risk patients for functional
11 decline during hospitalization would be useful for its prevention. Furthermore, no previous
12 study focused on subsequent clinical outcomes in patients with functional decline during
13 hospitalization. Therefore, we sought to clarify the risk factors for functional decline during
14 hospitalization in very old patients with ADHF and to compare the 1-year clinical outcomes
15 between the 2 groups of patients with and without functional decline during the
16 hospitalization for ADHF in a large Japanese observational database of hospitalized patients
17 for ADHF in the real-world clinical practice.

1 **Methods**

2 **Study Design, Setting, and Population**

3 The Kyoto Congestive Heart Failure (KCHF) registry is a physician-initiated,
4 prospective, observational, multicentre cohort study that enrolled consecutive patients who
5 were hospitalized for ADHF for the first time between October 1, 2014, and March 31, 2016.
6 These patients were admitted into 19 secondary and tertiary hospitals, including rural and
7 urban as well as large and small institutions, throughout Japan. The study protocol was
8 approved by the institutional review board of Kyoto University (approval number: E2311)
9 and each participating centre. A waiver of written informed consent from each patient was
10 granted by the institutional review boards of Kyoto University and each participating centre
11 because the study met the conditions of the Japanese ethical guidelines for epidemiological
12 study and the US policy for protecting human research participants.[6,7] This study followed
13 the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE)
14 reporting guideline.

15 The details of the KCHF study design and patient enrolment are described
16 elsewhere.[8–11] Briefly, we enrolled all patients with ADHF, as defined by the modified
17 Framingham criteria, who were admitted to the participating hospitals and patients who

1
2
3
4 1 underwent heart failure-specific treatment involving intravenous drugs within 24 hours after
5
6
7
8 2 hospital presentation. Patient records were anonymized before analysis. Data analysis was
9
10
11 3 conducted from August 2018 to October 2018.
12
13

14 4 Among 4056 patients enrolled in the KCHF registry, 3785 patients were discharged
15
16
17 5 alive after hospitalization for ADHF. Clinical follow-up data were collected in October 2017.
18
19
20
21 6 The attending physicians or research assistants at each participating hospital collected clinical
22
23
24 7 events after the index hospitalization from hospital charts or by contacting patients, their
25
26
27
28 8 relatives, or their referring physicians with consent. The present analysis had 2 objectives.
29
30
31 9 First, we sought to clarify the risk factors for functional decline during hospitalization of
32
33
34 10 ADHF patients. Second, we sought to compare the 1-year clinical outcomes between the 2
35
36
37
38 11 groups of patients with and without functional decline during the hospitalization for ADHF.
39
40
41 12 Among 4056 patients enrolled in the KCHF registry, the current study population consisted
42
43
44 13 of 3555 patients who were discharged alive and were assessed for functional decline during
45
46
47
48 14 hospitalization, excluding 271 patients who died during the index hospitalization, 99 patients
49
50
51 15 whose functional status before admission and/or at discharge was not available, and 131
52
53
54 16 patients who were bedridden before index hospitalization (Figure 1). The long-term follow-
55
56
57
58 17 up was censored at 1-year. The primary outcome measure in the current analysis was a
59
60

1
2
3
4 1 composite of all-cause death or heart failure hospitalization at 1-year. The secondary outcome
5
6
7
8 2 measures were all-cause death, heart failure hospitalization, and a composite of all-cause
9
10
11 3 death or all-cause hospitalization at 1-year.
12
13

14 **Definitions**

15
16
17 5 Physical activity before admission and at discharge was classified by mobility
18
19
20
21 6 status based on the definition of Japanese long-term care insurance into ambulatory
22
23
24 7 (including those patients using any aid such as stick), use of wheelchair outdoor only, use of
25
26
27
28 8 wheelchair indoor and outdoor, and bedridden state.[8] Functional decline was defined as the
29
30
31 9 decline of at least one stage on physical activity at discharge compared with pre-admission
32
33
34 10 status. In-hospital worsening heart failure was defined as additional intravenous drug
35
36
37
38 11 administration for heart failure, haemodialysis, or mechanical circulatory or respiratory
39
40
41 12 support, occurring >24 hours after therapy initiation.[12] In-hospital worsening renal function
42
43
44 13 was defined as >0.3 mg/dL increase in serum creatinine levels during the index
45
46
47
48 14 hospitalization.[13–15] Detailed definitions of baseline clinical characteristics including the
49
50
51 15 signs and symptoms of heart failure were described previously.[9] Missing values were
52
53
54 16 presented in eTable 1.
55
56

57 **Statistical Analysis**

1
2
3
4 1 Categorical variables were presented as numbers with percentages and compared
5
6
7
8 2 using χ^2 test. Continuous variables were expressed as the mean with standard deviation or
9
10
11 3 median with 25th to 75th percentiles, and compared using the Student's *t* test when normally
12
13
14 4 distributed or Wilcoxon rank-sum test when not normally distributed.
15
16

17
18 5 We compared baseline characteristics and clinical outcomes based on the presence
19
20
21 6 or absence of functional decline during the index hospitalization. A multivariable logistic
22
23
24 7 regression model was developed to identify clinical characteristics associated with an
25
26
27 8 increased risk for functional decline. We used 24 clinically relevant factors listed in Table 1
28
29
30
31 9 as potential independent risk factors in multivariable logistic regression models and estimated
32
33
34 10 the odd ratios (ORs) and 95% confidence intervals (CIs). We used the Kaplan-Meier method
35
36
37
38 11 to estimate the cumulative 1-year incidences of the outcome measures and assessed the
39
40
41 12 differences with the log-rank test. We expressed the associations of the functional decline
42
43
44 13 group with the no functional decline group for all outcome measures as hazard ratios (HRs)
45
46
47
48 14 with 95% CIs by multivariable Cox proportional hazard models incorporating 30 clinically
49
50
51 15 relevant risk-adjusting variables indicated in Table 1. We also conducted subgroup analyses
52
53
54 16 stratified by age, sex, LVEF, anaemia, albumin levels, body temperature, and the
55
56
57
58 17 symptomatic status at discharge (oedema and general malaise at discharge). In the
59
60

1
2
3
4 1 multivariable analysis and subgroup analyses, continuous variables were dichotomized by
5
6
7 2 clinically meaningful reference values or median values; age ≥ 80 years based on the median
8
9
10 3 value, LVEF $< 40\%$ based on the heart failure guideline of LVEF classification [16], BMI
11
12
13
14 4 ≤ 22 kg/m², renal dysfunction (eGFR < 30 ml/min/1.73m²) based on CKD grade, decreased
15
16
17 5 albumin levels (serum albumin < 3.0 g/dL), hyponatremia (serum sodium < 135 mEq/L),
18
19
20 6 elevated body temperature (body temperature $\geq 37.5^\circ\text{C}$) based on the cut-off value in
21
22
23
24 7 metabolic syndrome [17].
25
26

27 8 We performed an additional analysis using the data including those patients who
28
29
30 9 died during the index hospitalization and those who were bedridden before the index
31
32
33
34 10 hospitalization, and evaluated the factors associated with functional decline or in-hospital
35
36
37 11 mortality by constructing the multivariable adjusted Cox models. All statistical analyses were
38
39
40
41 12 conducted by a physician (H.Y.) and a statistician (T.M.) with JMP 13.0 or SAS 9.4 (both
42
43
44 13 SAS Institute Inc, Cary, NC). Two-tailed P-values less than 0.05 were considered statistically
45
46
47 14 significant.
48
49

50 15 **Patient and public involvement**

51 16 No patient involved.
52
53
54
55
56
57
58 17
59
60

1 **Results**

2 **Baseline Clinical Characteristics**

3 Among 3555 study patients, physical activity before admission included
4 ambulatory in 2949 patients (83%), wheelchair outdoor only in 272 patients (7.7%), and
5 wheelchair outdoor and indoor in 334 patients (9.4%). At hospital discharge, functional
6 decline was observed in 420 patients (14%) who were ambulatory before admission, in 80
7 patients (29%) who had used wheelchair outdoor only, and in 28 patients (8.4%) who had
8 used wheelchair outdoor and indoor. Consequently, decline in functional status was observed
9 in 528 patients (15%; functional decline group), while functional decline was not observed in
10 3027 patients (85%; no functional decline group) (eFigure 1). Wheelchair outdoor only
11 before admission were more prevalent in the functional decline group than in the no
12 functional decline group; however, 80% of patients in the functional decline group were
13 ambulatory before admission (Table 1).

14 Regarding the baseline clinical characteristics, the patients in the functional decline
15 group were older and had a higher prevalence of hypertension, prior stroke, renal
16 dysfunction, dementia, malignancy, anaemia, decreased albumin levels, and hyponatremia
17 (Table 1). There were no significant differences in previous heart failure hospitalization,

1
2
3
4 1 atrial fibrillation or flutter, previous myocardial infarction, chronic lung disease, and living
5
6
7
8 2 alone status as a social background between the 2 groups (Table 1). The functional decline
9
10
11 3 group was more likely to have a valvular aetiology, lower blood pressure, lower heart rate,
12
13
14 4 higher levels of brain natriuretic peptide (BNP) or N-terminal portion of proBNP (NT-
15
16
17 5 proBNP), and a higher LVEF (Table 1). The proportion of patients who achieved relief of
18
19
20
21 6 signs and symptoms on admission after the treatment in the emergency room was not
22
23
24 7 significantly different between the 2 groups (14% vs. 16%, P=0.25).
25
26

27 8 **Risk Factors for Functional Decline**

29
30
31 9 Among the baseline characteristics and status at hospital presentation, the following
32
33
34 10 independent risk factors for functional decline during hospitalization were identified by the
35
36
37 11 multivariable logistic regression analysis: age ≥ 80 years (OR 2.71; 95% CI 2.09–3.51),
38
39
40
41 12 women (OR 1.32; 95% CI 1.05–1.67), prior stroke (OR 1.67; 95% CI 1.28–2.19), dementia
42
43
44 13 (OR 2.26; 95% CI 1.74–2.95), ambulatory before admission (OR 1.74; 95% CI 1.29–2.35),
45
46
47 14 elevated body temperature (OR 1.91; 95% CI 1.31–2.79), New York Heart Association class
48
49
50
51 15 III or IV on admission (OR 1.54; 95% CI 1.07–2.22), decreased albumin levels (OR 1.76;
52
53
54 16 95% CI 1.32–2.34), hyponatremia (OR 1.49; 95% CI 1.10–2.03), renal dysfunction (OR 1.55;
55
56
57 17 95% CI 1.22–1.98) (Figure 2).
58
59
60

1 **In-hospital adverse events and status at discharge**

2 The median length of hospital stay was longer in the functional decline group than
3 in the no functional decline group (21 days vs. 15 days, $P < 0.001$). Regarding the in-hospital
4 adverse events, the prevalence of worsening heart failure, worsening renal function, and
5 stroke was higher in the functional decline group than in the no functional decline group
6 (Table 2). The proportion of patients with symptoms such as oedema and general malaise at
7 discharge was higher in the functional decline group than in the no functional decline group
8 (Table 1). Consequently, the proportion of patients in the functional decline group discharged
9 to home was also lower (47% vs. 90%, $P < 0.001$). Regarding medical treatment at discharge,
10 angiotensin-converting enzyme inhibitor or angiotensin receptor blocker (ACEI or ARB), and
11 beta blocker were less often prescribed in the functional decline group than in the no
12 functional decline group (Table 1).

13 **Long-term outcomes: functional decline vs. no functional decline groups**

14 Follow-up rate at 1-year was 96%. The cumulative 1-year incidence of the primary
15 outcome measure (a composite of all-cause death or heart failure hospitalization) in the
16 functional decline group was significantly higher than that in the no functional decline group
17 (49% vs. 31%, log-rank $P < 0.001$) (Figure 3). After adjusting for baseline characteristics, the

1
2
3
4 1 higher risk of the functional decline group relative to the no functional decline group
5
6
7
8 2 remained significant (adjusted HR, 1.46; 95%CI, 1.24–1.71; P<0.001) (Figure 3 and Table
9
10
11 3). The cumulative 1-year incidence of all-cause death was also significantly higher in the
12
13
14 4 functional decline group than in the no functional decline group. Even after adjusting
15
16
17 5 confounders, the excess mortality risk of the functional decline group relative to the no
18
19
20
21 6 functional decline group remained significant (Figure 3 and Table 3). The cumulative 1-year
22
23
24 7 incidence of heart failure hospitalization was also significantly higher in the functional
25
26
27
28 8 decline group than in the no functional decline group. However, the adjusted risk of the
29
30
31 9 functional decline group relative to the no functional decline group for heart failure
32
33
34 10 hospitalization was no longer significant (Figure 3 and Table 3). The cumulative 1-year
35
36
37
38 11 incidence of a composite of all-cause death or all-cause hospitalization was significantly
39
40
41 12 higher in the functional decline group than in the no functional decline group. After adjusting
42
43
44 13 confounders, the higher risk of the functional decline group relative to the no functional
45
46
47
48 14 decline group remained significant (Figure 3 and Table 3). In the subgroup analyses, there
49
50
51 15 were no interactions between those subgroup factors and the association of functional decline
52
53
54 16 with the primary outcome measure (eFigure 2).

57 **Additional analysis on the risk factors for functional decline or in-hospital mortality**
58
59
60

1
2
3
4 1 The risk factors for functional decline or in-hospital mortality in a total of 4056
5
6
7
8 2 patients were similar to the risk factors for functional decline. LVEF <40% (OR, 1.24; 95%
9
10
11 3 CI, 1.00–1.52; P = 0.047) and acute coronary syndrome (OR, 1.76; 95% CI, 1.19–2.60; P =
12
13
14 4 0.005) that were not included in the risk factors for functional decline emerged as the risk
15
16
17
18 5 factors for functional decline or in-hospital mortality (eTable 2). Meanwhile, among the risk
19
20
21 6 factors for functional decline, women (OR, 1.13; 95% CI, 0.93–1.38; P = 0.22) was not
22
23
24 7 included in the risk factors for functional decline or in-hospital mortality (Figure 2 and
25
26
27
28 8 eTable 2).

9 10 **Discussion**

11 The main findings of the present study investigating the prevalence and risk factors
12 of functional decline during hospitalization, and its relationship with post-discharge outcomes
13 in patients with ADHF hospitalization were as follows; 1) Functional decline during ADHF
14 hospitalization occurred in 15% of patients, and 80% of those with functional decline were
15 ambulatory before admission; 2) The independent baseline risk factors associated with
16 functional decline included age ≥ 80 years, women, prior stroke, dementia, ambulatory before
17 admission, elevated body temperature, NYHA class III or IV on admission, decreased

1
2
3
4 1 albumin levels, hyponatremia, and renal dysfunction. 3) Functional decline during the index
5
6
7 2 hospitalization was associated with higher long-term risk for a composite of all-cause death
8
9
10
11 3 or heart failure hospitalization.
12
13

14 4 This is the first large-scale contemporary multicentre study reporting the
15
16
17 5 prevalence of functional decline in patients hospitalized for ADHF. Of note, we identified the
18
19
20
21 6 severity of symptoms or patient status specific for heart failure was associated with functional
22
23
24 7 decline independent of well-known factors in acute medical illness [18–20]. Functional
25
26
27 8 decline is an inevitable consequence in aged people, but hospitalization accelerates the
28
29
30
31 9 decline [20–22]. Functional declines have been found to be related not only to impairment of
32
33
34 10 independence and quality of life (QOL), but also to increased health service use, higher risk
35
36
37 11 for institutionalization, and higher risk for mortality [23–27]. Indeed, in the present study, the
38
39
40
41 12 proportion of patients discharged to home was lower in the functional decline group than in
42
43
44 13 the no functional decline group, suggesting impaired QOL after discharge. Also, the long-
45
46
47 14 term mortality was worse in the functional decline group than in the no functional decline
48
49
50
51 15 group. Therefore, it is important to recognize risk factors of functional decline. In previous
52
53
54 16 studies of hospitalized patients with acute medical illness, the predictors of functional decline
55
56
57 17 in hospitalized elderly patients were older age, admission diagnosis, lower functional status,
58
59
60

1 impaired cognitive status, comorbidities, and length of hospital stay.[18–20] These findings
2 were confirmed in the setting of ADHF in our present study. In addition, findings specific for
3 ADHF such as the dyspnoea or hyponatremia was associated with functional decline, which
4 were also reported to be the risk factors for in-hospital mortality in ADHF [28]. The
5 prevalence of oedema and general malaise at discharge was higher in the functional decline
6 group. Early achievement of successful ADHF treatment might reduce the risk of functional
7 decline, although the present observational study could not address the cause-effect
8 relationship between the functional decline and the symptomatic status at discharge.

9 There might be several possible strategies to prevent functional decline during
10 ADHF hospitalization. The first is the early improvement of hemodynamic status to avoid
11 worsening heart failure. The prevalence of worsening heart failure was higher in the
12 functional decline group. As functional decline associated with hospitalization begins within
13 48 hours of admission, early improvement of heart failure to reduce the incidence of
14 hospitalization-associated disability is one of the main goals of care.[28] Second, it would be
15 important to be adequately aware high-risk patients to make aggressive intervention for
16 preventing functional decline. We identified the risk factors among the baseline
17 characteristics in ADHF patients. In addition, the adverse events during hospitalization may

1 be tightly related to the functional decline. Stroke is one of causes of functional decline and
2
3
4
5
6
7
8 observed in 5.1% of patients with functional decline. Third, a strategy for the prevention of
9
10
11 functional decline might be the seamless rehabilitation and comprehensive geriatric
12
13
14 management through a multidisciplinary team approach.[29–32] In addition, the subgroup
15
16
17
18 analysis showed that there were no interactions between those subgroup factors and the
19
20
21 association of functional decline with the primary outcome measure. Thus, prevention of
22
23
24 functional decline would have an impact on improving outcomes in all of the patients with
25
26
27
28 ADHF. One possible strategy could be immediate, tailored physical function rehabilitation
29
30
31 during and after heart failure hospitalization.[33]
32

33 **Limitations**

34
35
36
37 This study has several limitations. First, we adopted simple classification of
38
39
40 functional status as ambulatory, use of wheelchair outdoor only, use of wheelchair indoor and
41
42
43 outdoor, and bedridden state based on the definition of Japanese long-term care insurance.
44
45
46
47 The categorization scheme is an easy to understand but coarse measure with very large
48
49
50 gradations inherent in each single stage and therefore very likely substantially underestimated
51
52
53
54 the prevalence of meaningful functional decline. Second, we did not collect data regarding
55
56
57
58 on-site and outpatient rehabilitation and nutritional support. However, a team-based approach
59
60

1 for heart failure patients was adapted in all the participating centres in the present study.

2 Third, we did not include the status at discharge or adverse in-hospital events in the analysis

3 for the risk factor for functional decline, because the cause-effect relationship was not clear.

4 Fourth, data on post-discharge medication and change of functional status after discharge

5 from the index hospitalization were not collected, and not analysed in the analysis for the

6 long-term outcomes. Fifth, as with any observational study, the possibility of selection bias

7 and residual confounding cannot be excluded, although we adjusted for 29 variables as most

8 conceivable confounders.

9 **Conclusions**

10 Independent risk factors of functional decline in ADHF patients were related to

11 both frailty and severity of heart failure. Functional decline during ADHF hospitalization was

12 associated with unfavourable post-discharge outcomes.

1 **Acknowledgment**

2 We gratefully acknowledge the contributions from KCHF study investigators (Hidenori
3 Yaku, MD; Takao Kato, MD; Neiko Ozasa, MD; Erika Yamamoto, MD; Yusuke Yoshikawa,
4 MD; Tetsuo Shioi, MD; Koichiro Kuwahara, MD; Takeshi Kimura, MD, at Kyoto University
5 Hospital, Kyoto, Japan, Moritake Iguchi, MD; Yugo Yamashita, MD, Masaharu Akao, MD,
6 at National Hospital Organization Kyoto Medical Centre, Kyoto, Japan, Masashi Kato, MD;
7 Shinji Miki, MD, at Mitsubishi Kyoto Hospital, Kyoto, Japan, Mamoru Takahashi, MD, at
8 Shimabara Hospital, Kyoto, Japan, Tsuneaki Kawashima, MD; Takafumi Yagi, MD, at
9 Okamoto Memorial Hospital, Toshikazu Jinnai, MD; Takashi Konishi, MD, at Japanese Red
10 Cross Otsu Hospital, Otsu, Japan, Yasutaka Inuzuka, MD; Shigeru Ikeguchi, MD, at Shiga
11 General Hospital, Moriyama, Japan, Tomoyuki Ikeda, MD; Yoshihiro Himura, MD, at
12 Hikone Municipal Hospital, Hikone, Japan, Kazuya Nagao, MD; Tsukasa Inada, MD, at
13 Osaka Red Cross Hospital, Osaka, Japan, Kenichi Sasaki, MD; Moriaki Inoko, MD, at Kitano
14 Hospital, Osaka, Japan, Takafumi Kawai, MD; Tomoki Sasa, MD; Mitsuo Matsuda, MD, at
15 Kishiwada City Hospital, Kishiwada, Japan, Akihiro Komasa, MD; Katsuhisa Ishii, MD, at
16 Kansai Electric Power Hospital, Osaka, Japan, Yodo Tamaki, MD; Yoshihisa Nakagawa,
17 MD, at Tenri Hospital, Tenri, Japan, Ryoji Taniguchi, MD; Yukihito Sato, MD; Yoshiki

1 Takatsu, MD, at Hyogo Prefectural Amagasaki General Medical Centre, Amagasaki, Japan,
2
3
4
5
6
7
8 2 Takeshi Kitai, MD;, Ryouyuke Murai, MD; Yutaka Furukawa, MD, at Kobe City Medical
9
10
11 3 Centre General Hospital, Kobe, Japan, Mitsunori Kawato, MD, at Kobe City Nishi-Kobe
12
13
14 4 Medical Centre, Kobe, Japan, Yasuyo Motohashi, MD; Kanae Su, MD; Mamoru Toyofuku,
15
16
17 5 MD; Takashi Tamura, MD, at Japanese Red Cross Wakayama Medical Centre, Wakayama,
18
19
20
21 6 Japan, Reiko Hozo, MD; Ryusuke Nishikawa, MD; Hiroki Sakamoto, MD, at Shizuoka
22
23
24 7 General Hospital, Shizuoka, Japan, Yuichi Kawase, MD; Keiichiro Iwasaki, MD; Kazushige
25
26
27 8 Kadota, MD, at Kurashiki Central Hospital, Kurashiki, Japan, and Takashi Morinaga, MD;
28
29
30
31 9 Yohei Kobayashi, MD; Kenji Ando, MD, at Kokura Memorial Hospital, Kokura, Japan.).
32
33

34 10 **Sources of Funding**

35
36
37 11 This study is supported by a grant from the Japan Agency for Medical Research and
38
39
40
41 12 Development (18059186) to TK, KK, NO. The founder had no role in the study design,
42
43
44 13 collection, analysis or interpretation of the data, writing the manuscript, or the decision to
45
46
47 14 submit the paper for publication.
48
49

50 51 15 **Competing interests**

52
53
54 16 None declared.
55

56 57 17 **Author Contributions**

- 1
2
3
4 1 Drs Yaku and T. Kato had full access to all of the data in the study and take responsibility for
5
6
7
8 2 the integrity of the data and the accuracy of the data analysis.
9
10
11 3 Concept and design: Yaku, T. Kato, Morimoto, Tamaki, Ozasa, Yamamoto, Kitai, M. Kato,
12
13
14 4 Kimura.
15
16
17 5 Acquisition, analysis, or interpretation of data: Yaku, T. Kato, Morimoto, Inuzuka, Tamaki,
18
19
20
21 6 Yoshikawa, Ikeda, Furukawa, Kuwahara.
22
23
24 7 Drafting of the manuscript: Yaku, T. Kato, Kimura.
25
26
27 8 Critical revision of the manuscript for important intellectual content: Yaku, T. Kato,
28
29
30
31 9 Morimoto, Inuzuka, Tamaki, Yamamoto, Yoshikawa, Kitai, Kuwahara, Kimura.
32
33
34 10 Statistical analysis: Yaku, T. Kato, Morimoto.
35
36
37
38 11 Administrative, technical, or material support: T. Kato, Sato, Kimura.
39
40
41 12 Supervision: Inuzuka, Ozasa, Kitai, Furukawa, Nakagawa, Sato, Kuwahara, Kimura.
42
43

13 **Ethics approval**

- 14 The study was approved by the Institutional Review Boards of Kyoto University Graduate
15 School of Medicine (approval number: E2311), Shiga General Hospital (approval number:
16 20141120-01), Tenri Hospital (approval number: 640), Kobe City Medical Centre General
17 Hospital (approval number: 14094), Hyogo Prefectural Amagasaki General Medical Centre

1 (approval number: Rinri 26-32), National Hospital Organization Kyoto Medical Centre
2
3
4
5
6
7
8 2 (approval number:14-080), Mitsubishi Kyoto Hospital (approved 11/12/2014), Okamoto
9
10
11 3 Memorial Hospital (approval number: 201503), Japanese Red Cross Otsu Hospital (approval
12
13
14 4 number: 318), Hikone Municipal Hospital (approval number: 26-17), Japanese Red Cross
15
16
17 5 Osaka Hospital (approval number: 392), Shimabara Hospital (approval number: E2311),
18
19
20
21 6 Kishiwada City Hospital (approval number:12), Kansai Electric Power Hospital (approval
22
23
24 7 number: 26-59), Shizuoka General Hospital (approval number: Rin14-11-47), Kurashiki
25
26
27 8 Central Hospital (approval number: 1719), Kokura Memorial Hospital (approval number:
28
29
30
31 9 14111202), Kitano Hospital (approval number: P14-11-012), and Japanese Red Cross
32
33
34 10 Wakayama Medical Centre (approval number: 328).

11 **Data sharing**

12 All data relevant to the study are included in the article or uploaded as supplementary
13 information. No additional data available.
14

1
2
3
4 **1 References**
5
6
7

- 8 2 1 Manton KG. A longitudinal study of functional change and mortality in the United
9
10 States. *J Gerontol* 1988;**43**:S153-61.<http://www.ncbi.nlm.nih.gov/pubmed/2971088>
11 3
12
13
14 4 2 Boyd CM, Ricks M, Fried LP, *et al.* Functional decline and recovery of activities of
15
16 daily living in hospitalized, disabled older women: the Women's Health and Aging
17 5
18 Study I. *J Am Geriatr Soc* 2009;**57**:1757–66. doi:10.1111/j.1532-5415.2009.02455.x
19 6
20
21
22
23
24 7 3 Guralnik JM, Alexih L, Branch LG. Medical and Long-Term Care Costs When Older
25
26 Persons Become More Dependent Intentional Weight Loss and 13-Year Diabetes
27 8
28 Incidence in Overweight Adults. *Am J Public Health* 2002;**92**:1244–5.
29 9
30
31
32
33
34 10 4 Gill TM, Allore HG, Holford TR, *et al.* Hospitalization, restricted activity, and the
35
36 development of disability among older persons. *J Am Med Assoc* 2004;**292**:2115–24.
37 11
38
39
40
41 12
42
43
44 13 5 Sager MA, Franke T, Inouye SK, *et al.* Functional outcomes of acute medical illness
45
46 and hospitalization in older persons. *Arch Intern Med* 1996;**156**:645–
47 14
48
49
50
51 15
52
53
54 16 6 Ministry of Education, Culture, Sports, Science and Technology Ministry of Health L
55
56
57 17
58
59
60 and W. Japan's ethical guidelines for epidemiologic research.

- 1
2
3
4 1 2002.http://www.lifescience.mext.go.jp/files/pdf/n796_01.pdf
5
6
7
8 2 7 45 Code of Federal Regulations 46.116(d). 2009;:4–
9
10
11 3 [5.https://www.hhs.gov/ohrp/regulations-and-policy/regulations/45-cfr-](https://www.hhs.gov/ohrp/regulations-and-policy/regulations/45-cfr-)
12
13
14 4 [46/index.html#46.116](https://www.hhs.gov/ohrp/regulations-and-policy/regulations/45-cfr-46/index.html#46.116)
15
16
17 5 8 Yamamoto E, Kato T, Ozasa N, *et al.* Kyoto Congestive Heart Failure (KCHF) study:
18
19
20
21 6 rationale and design. *ESC Hear Fail* 2017;**4**:216–23. doi:10.1002/ehf2.12138
22
23
24 7 9 Yaku H, Ozasa N, Morimoto T, *et al.* Demographics, Management, and In-Hospital
25
26
27
28 8 Outcome of Hospitalized Acute Heart Failure Syndrome Patients in Contemporary
29
30
31 9 Real Clinical Practice in Japan - Observations From the Prospective, Multicenter
32
33
34 10 Kyoto Congestive Heart Failure (KCHF) Registry. *Circ J* 2018;**82**:2811–9.
35
36
37 11 doi:10.1253/circj.CJ-17-1386
38
39
40
41 12 10 Yaku H, Kato T, Morimoto T, *et al.* Association of Mineralocorticoid Receptor
42
43
44 13 Antagonist Use with All-Cause Mortality and Hospital Readmission in Older Adults
45
46
47
48 14 with Acute Decompensated Heart Failure. *JAMA Netw Open* 2019;**2**:1–14.
49
50
51 15 doi:10.1001/jamanetworkopen.2019.5892
52
53
54 16 11 Su K, Kato T, Toyofuku M, *et al.* Association of Previous Hospitalization for Heart
55
56
57
58 17 Failure With Increased Mortality in Patients Hospitalized for Acute Decompensated
59
60

- 1
2
3
4 1 Heart Failure. *Circ Reports* 2019;**1**:517–24. doi:10.1253/circrep.CR-19-0054
5
6
7
8 2 12 Butler J, Gheorghiade M, Kelkar A, *et al.* In-hospital worsening heart failure. *Eur J*
9
10
11 3 *Heart Fail* 2015;**17**:1104–13. doi:10.1002/ejhf.333
12
13
14 4 13 Filippatos G, Farmakis D, Parissis J. Renal dysfunction and heart failure: Things are
15
16
17 5 seldom what they seem. *Eur Heart J* 2014;**35**:416–8. doi:10.1093/eurheartj/ehf515
18
19
20
21 6 14 Vardeny O, Wu DH, Desai A, *et al.* Influence of baseline and worsening renal function
22
23
24 7 on efficacy of spironolactone in patients with severe heart failure: Insights from rales
25
26
27 8 (randomized aldactone evaluation study). *J Am Coll Cardiol* 2012;**60**:2082–9.
28
29
30 9 doi:10.1016/j.jacc.2012.07.048
31
32
33
34 10 15 Clark H, Krum H, Hopper I. Worsening renal function during renin-angiotensin-
35
36
37 11 aldosterone system inhibitor initiation and long-term outcomes in patients with left
38
39
40
41 12 ventricular systolic dysfunction. *Eur J Heart Fail* 2014;**16**:41–
42
43
44 13 8.[http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L3](http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L372684240%5Cnhttp://dx.doi.org/10.1002/ejhf.13)
45
46
47 14 [72684240%5Cnhttp://dx.doi.org/10.1002/ejhf.13](http://dx.doi.org/10.1002/ejhf.13)
48
49
50
51 15 16 Ponikowski P, Voors AA, Anker SD, *et al.* 2016 ESC Guidelines for the diagnosis and
52
53
54 16 treatment of acute and chronic heart failure: The Task Force for the diagnosis and
55
56
57 17 treatment of acute and chronic heart failure of the European Society of Cardiology
58
59
60

- 1
2
3
4 1 (ESC). Developed with the special contribution . *Eur J Heart Fail* 2016;**18**:891–975.
5
6
7
8 2 doi:10.1002/ejhf.592
9
10
11 3 17 Oda E, Oohara K, Abe A, *et al*. The optimal cut-off point of C-reactive protein as an
12
13
14 4 optional component of metabolic syndrome in Japan. *Circ J* 2006;**70**:384–8.
15
16
17 5 doi:10.1253/circj.70.384
18
19
20
21 6 18 Stuck AE, Walthert JM, Nikolaus T, *et al*. Risk factors for functional status decline in
22
23
24 7 community-living elderly people: a systematic literature review. *Soc Sci Med*
25
26
27 8 1999;**48**:445–69. doi:10.1016/S0277-9536(98)00370-0
28
29
30
31 9 19 McCusker J, Kakuma R, Abrahamowicz M. Predictors of functional decline in
32
33
34 10 hospitalized elderly patients: a systematic review. *J Gerontol A Biol Sci Med Sci*
35
36
37 11 2002;**57**:M569-77.<http://www.ncbi.nlm.nih.gov/pubmed/12196493>
38
39
40
41 12 20 Covinsky KE, Palmer RM, Fortinsky RH, *et al*. Loss of independence in activities of
42
43
44 13 daily living in older adults hospitalized with medical illnesses: increased vulnerability
45
46
47 14 with age. *J Am Geriatr Soc* 2003;**51**:451–
48
49
50
51 15 8.<http://www.ncbi.nlm.nih.gov/pubmed/12657063>
52
53
54 16 21 Inouye SK, Bogardus ST, Baker DI, *et al*. The hospital elder life program: A model of
55
56
57 17 care to prevent cognitive and functional decline in older hospitalized patients. *J Am*
58
59
60

- 1
2
3
4 1 *Geriatr Soc* 2000;**48**:1697–706. doi:10.1111/j.1532-5415.2000.tb03885.x
- 5
6
7 2 22 Pandharipande PP, Girard TD, Jackson JC, *et al.* Long-term cognitive impairment after
8
9
10
11 3 critical illness. *N Engl J Med* 2013;**369**:1306–16. doi:10.1056/NEJMoa1301372
12
13
14 4 23 Hirvensalo M, Rantanen T, Heikkinen E. Mobility difficulties and physical activity as
15
16
17 5 predictors of mortality and loss of independence in the community-living older
18
19
20
21 6 population. *J Am Geriatr Soc* 2000;**48**:493–8. doi:10.1111/j.1532-
22
23
24 7 5415.2000.tb04994.x
25
26
27 8 24 Greiner PA, Snowdon DA, Schmitt FA. The loss of independence in activities of daily
28
29
30 9 living: The role of low normal cognitive function in elderly nuns. *Am J Public Health*
31
32
33
34 10 1996;**86**:62–6. doi:10.2105/AJPH.86.1.62
35
36
37 11 25 Ganguli M, MPH ES, PhD SB, *et al.* Cognitive Impairment and the Use of Health
38
39
40
41 12 Services in an Elderly Rural Population: The MoVIES Project. *J Am Geriatr Soc*
42
43
44 13 1993;**41**:1065–70. doi:10.1111/j.1532-5415.1993.tb06453.x
45
46
47 14 26 Barberger-Gateau P, Fabrigoule C. Disability and cognitive impairment in the elderly.
48
49
50
51 15 *Disabil Rehabil* 1997;**19**:175–93. <http://www.ncbi.nlm.nih.gov/pubmed/9184783>
52
53
54 16 27 Black SA, Rush RD. Cognitive and functional decline in adults aged 75 and older. *J*
55
56
57 17 *Am Geriatr Soc* 2002;**50**:1978–86. doi:10.1046/j.1532-5415.2002.50609.x
58
59
60

- 1
2
3
4 1 28 Hirsch CH, Sommers L, Olsen A, *et al.* The natural history of functional morbidity in
5
6
7
8 2 hospitalized older patients. *J Am Geriatr Soc* 1990;**38**:1296–
9
10
11 3 303.<http://www.ncbi.nlm.nih.gov/pubmed/2123911>
12
13
14 4 29 O'Connor CM, Whellan DJ, Lee KL, *et al.* Efficacy and safety of exercise training in
15
16
17 5 patients with chronic heart failure: HF-ACTION randomized controlled trial. *JAMA*
18
19
20
21 6 2009;**301**:1439–50. doi:10.1001/jama.2009.454
22
23
24 7 30 Baztán JJ, Suárez-García FM, López-Arrieta J, *et al.* Effectiveness of acute geriatric
25
26
27 8 units on functional decline, living at home, and case fatality among older patients
28
29
30
31 9 admitted to hospital for acute medical disorders: Meta-analysis. *BMJ* 2009;**338**:334–6.
32
33
34 10 doi:10.1136/bmj.b50
35
36
37 11 31 Fox MT, Persaud M, Maimets I, *et al.* Effectiveness of acute geriatric unit care using
38
39
40
41 12 acute care for elders components: A systematic review and meta-analysis. *J Am*
42
43
44 13 *Geriatr Soc* 2012;**60**:2237–45. doi:10.1111/jgs.12028
45
46
47
48 14 32 Bachmann S, Finger C, Huss A, *et al.* Inpatient rehabilitation specifically designed for
49
50
51 15 geriatric patients: Systematic review and meta-analysis of randomised controlled trials.
52
53
54 16 *BMJ* 2010;**340**:1230. doi:10.1136/bmj.c1718
55
56
57 17 33 Reeves GR, Whellan DJ, Duncan P, *et al.* Rehabilitation Therapy in Older Acute Heart
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 Failure Patients (REHAB-HF) trial: Design and rationale. *Am Heart J* 2017;**185**:130–

2 9. doi:10.1016/j.ahj.2016.12.012

3

4

For peer review only

1
2
3
4 **1 Figure legends**
5

6
7
8 **2 Figure 1. Patient flowchart.** KCHF, Kyoto Congestive Heart Failure; ADHF, acute
9
10
11 decompensated heart failure.
12

13
14 **4 Figure 2. Clinical factors associated with functional decline during hospitalization in the**
15
16
17
18 **5 univariate and multivariable logistic regression models.** OR, odds ratio; CI, confidence
19
20
21 interval; BMI, body mass index; HF, heart failure; BP, blood pressure; NYHA, New York
22
23
24 Heart Association; LVEF, left ventricular ejection; eGFR, estimated glomerular filtration rate.
25

26
27
28 **8 Figure 3. The Cumulative incidences for the primary outcome measure (A), for all-**
29
30
31 **9 cause death (B), for HF hospitalization (C), and for a composite of all-cause death or all-**
32
33
34 **10 cause hospitalization (D) according to the presence or absence of functional decline.**
35
36
37
38 **11 HF=heart failure, HR=hazard ratio, CI=confidence interval.**
39

40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1. Patient Characteristics

	Functional decline	No functional decline	P value
	N=528	N=3027	
Clinical characteristics			
Age, years	85 [80–89]	79 [70–85]	<0.001
Age ≥80 years*†	399 (76)	1407 (46)	<0.001
Women*†	294 (56)	1278 (42)	<0.001
BMI, kg/m ²	22.0±4.0	23.1±4.5	<0.001
BMI ≤22 kg/m ² *†	269 (55)	1281 (44)	<0.001
Medical history			
Prior heart failure hospitalization*†	186 (36)	1077 (36)	0.92
Atrial fibrillation or flutter	220 (42)	1263 (42)	0.98
Hypertension*†	406 (77)	2174 (72)	0.02
Diabetes mellitus*†	187 (35)	1145 (38)	0.29
Prior myocardial infarction*†	112 (21)	681 (23)	0.51
Prior stroke*†	125 (24)	432 (14)	<0.001
Current smoking*†	28 (5.5)	425 (14)	<0.001
Malignancy	97 (18)	419 (14)	0.006
Chronic lung disease*†	41 (7.8)	247 (8.2)	0.76
Dementia*†	175 (33)	423 (14)	<0.001
Social backgrounds at admission			
Poor medical adherence	100 (19)	498 (16)	0.16
Living alone*†	127 (24)	652 (22)	0.20
Public assistance	24 (4.6)	186 (6.1)	0.14
Functional status before admission			
Ambulatory*†	420 (80)	2529 (84)	0.02
Use of wheelchair [outdoor only]	80 (15)	192 (6.3)	<0.001
Use of wheelchair [outdoor and indoor]	28 (5.3)	306 (10)	<0.001
Origin			
Ischemic	134 (25)	820 (27)	0.41
Acute coronary syndrome*†	36 (6.8)	166 (5.5)	0.22
Hypertensive	131 (25)	754 (25)	0.96
Valvular	124 (23)	565 (19)	<0.001

1				
2				
3	Cardiomyopathy	54 (10)	492 (16)	<0.001
4				
5	Vital signs and symptoms at presentation			
6				
7	BP, mmHg			
8	Systolic BP	144±32	149±35	0.003
9				
10	Systolic BP ≥140 mmHg	275 (53)	1741 (58)	0.03
11				
12	Systolic BP <90 mmHg*†	12 (2.3)	76 (2.5)	0.76
13				
14	Diastolic BP	81±23	86±24	<0.001
15	Heart rate, beat/min	93±27	96±28	0.001
16				
17	Heart rate <60 beat/min*†	44 (8.5)	195 (6.5)	0.11
18	Body temperature, °C	36.6±0.7	36.5±0.6	<0.001
19				
20	Body temperature ≥37.5°C*†	58 (11)	154 (5.3)	<0.001
21				
22	Rhythms at presentation			
23	Sinus rhythm	280 (53)	1715 (57)	0.12
24				
25	Atrial fibrillation or flutter*†	198 (38)	1085 (36)	0.47
26				
27	NYHA class III or IV*†	482 (92)	2598 (73)	<0.001
28				
29	Tests at admission			
30	LVEF	48±16	46±16	0.02
31				
32	HFrEF (EF<40%)*†	167 (32)	1148 (38)	0.006
33				
34	HFmrEF (EF 40–49%)	117 (22)	566 (19)	0.06
35				
36	HFpEF (EF ≥50%)	242 (46)	1305 (43)	0.24
37	Haemoglobin, g/dL	11.0±2.1	11.7±2.4	<0.001
38				
39	Anaemia*†‡	401 (76)	1946 (64)	<0.001
40	BNP, pg/ml	782 [448–1410]	687 [375–1214]	<0.001
41				
42	NT-proBNP, pg/ml	10795 [3450–18000]	5416 [2629–11438]	0.001
43				
44	Creatinine, mg/dL	1.2 [0.8–1.6]	1.1 [0.8–1.6]	0.21
45	eGFR, ml/min/1.73m ²	38 [24–54]	46 [30–62]	<0.001
46				
47	eGFR <30 ml/min/1.73m ² *†	195 (37)	747 (25)	<0.001
48				
49	Blood urea nitrogen, mg/dL	28 (20–39)	23 (17–33)	<0.001
50				
51	Albumin, g/dL	3.3±0.5	3.5±0.5	<0.001
52				
53	Albumin <3.0 g/dL*†	112 (22)	332 (11)	<0.001
54				
55	Sodium, mEq/L	138±4.7	139±4.1	<0.001
56				
57	Sodium <135 mEq/L*†	83 (16)	325 (11)	0.001
58				
59	Potassium, mEq/L	4.3±0.8	4.2±0.6	0.03
60				
	Clinical signs and symptoms at discharge			

1				
2				
3	Oedema†	89 (17)	320 (11)	<0.001
4	General malaise†	152 (31)	388 (14)	<0.001
5				
6	Medications at discharge			
7				
8	Number of drugs prescribed	8 (6–11)	9 (6–11)	0.12
9				
10	Loop diuretics†	428 (81)	2472 (82)	0.74
11				
12	ACEI or ARB†	242 (46)	1838 (61)	<0.001
13				
14	MRA†	208 (39)	1409 (47)	0.002
15				
16	Beta blocker†	287 (54)	2101 (69)	<0.001
17				
18	Tolvaptan	76 (14)	299 (9.9)	0.002
19	Functional status at discharge			
20				
21	Ambulatory	0	2682 (89)	<0.001
22				
23	Use of wheelchair [outdoor only]	184 (35)	160 (5.3)	<0.001
24				
25	Use of wheelchair [outdoor and indoor]	261 (49)	185 (6.1)	<.0001
26				
27	Bedridden	83 (16)	0	<0.001
28	Living place after discharge			
29				
30	Home	247 (47)	2709 (90)	<0.001
31				
32	Hospital	225 (43)	180 (6.0)	<0.001
33				
34	Institution for the aged	50 (9.5)	114 (3.8)	<0.001
35				
36	Other	4 (0.8)	17 (0.6)	0.59

Abbreviations: BMI, body mass index; BP, blood pressure; NYHA, New York Heart Association; LVEF, left ventricular ejection fraction; HF_rEF, heart failure with reduced ejection fraction; HF_{mr}EF, heart failure with mid-range ejection fraction; HF_{pe}EF, heart failure with preserved ejection fraction; BNP, brain-type natriuretic peptide; NT-proBNP, N-terminal-proBNP; eGFR, estimated glomerular filtration rate; ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; MRA, mineralocorticoid receptor antagonist.

Continuous variables were presented as mean ± SD or median with [interquartile range]. Categorical variables were presented as number (percentage).

* Risk-adjusting variables were selected for multivariable logistic regression models.

† Risk-adjusting variables were selected for multivariable Cox proportional hazard models.

‡ Defined by the World Health Organization criteria (haemoglobin <12 g/dL for women and <13 g/dL for men).

Table 2. In-hospital Management and Outcome

	Functional decline	No functional decline	P value
	N=528	N=3027	
In-hospital management			
Management in the emergency room			
Respiratory management			
Oxygen inhalation	295 (56)	1382 (46)	<0.001
NIPPV	82 (16)	423 (14)	0.35
Intubation	11 (2.1)	53 (1.8)	0.60
Intravenous drugs within 24 hours after hospital presentation			
Inotropes	101 (19)	405 (13)	<0.001
Furosemide	446 (85)	2536 (84)	0.69
In-hospital clinical outcomes			
In-hospital adverse events			
Stroke	27 (5.1)	26 (0.9)	<0.001
Worsening heart failure	130 (25)	490 (16)	<0.001
Worsening renal function	244 (47)	992 (33)	<0.001
In-hospital infection	104 (20)	258 (8.5)	<0.001
Length of stay, day	21 [14–37]	15 [11–22]	<0.001

Abbreviations: NIPPV, non-invasive intermittent positive pressure ventilation.

1 **Table 3. Clinical outcomes in the entire cohort**

Outcomes	Functional decline	No functional decline	Unadjusted HR (95% CI)	P value	Adjusted HR (95% CI)	P value
	N of patients with event / N of patients at risk (Cumulative 1-year incidence [%])	N of patients with event / N of patients at risk (Cumulative 1-year incidence [%])				
All-cause death or HF hospitalization	243/528 (49)	902/3027 (31)	1.95 (1.71–2.21)	<0.001	1.46 (1.24–1.71)	<0.001
All-cause death	174/528 (36)	386/3027 (13)	3.02 (2.58–3.53)	<0.001	2.12 (1.74–2.58)	<0.001
HF hospitalization	116/528 (28)	663/3027 (23)	1.25 (1.04–1.50)	0.02	1.03 (0.83–1.28)	0.81
All-cause death or All-cause hospitalization	279/528 (57)	1186/3027 (40)	1.69 (1.50–1.91)	<0.001	1.39 (1.20–1.61)	<0.001

The number of patients with at least one event was counted through the 1-year follow-up period.

Abbreviations: HF, heart failure; HR, hazard ratio; CI, confidence interval.

KCHF registry

4056 patients hospitalized with ADHF
(Oct 2014-Mar 2016, 19 centers in Japan)

In-hospital death during index hospitalization (N=271)

Excluded (N=230)

No data about functional status (n = 99)

Bedridden before index hospitalization (n = 131)

Study population:

Patients discharged alive assessed for functional decline during hospitalization
3555 patients

Functional decline: 528 patients

No functional decline: 3027 patients




Figure 2. Clinical factors associated with functional decline during hospitalization in the univariate and multivariable logistic regression models.

Figure 3A

All-cause death or HF hospitalization




Figure 3B

All-cause death




Figure 3C

HF hospitalization




Figure 3D

All-cause death or All-cause hospitalization




Figure 3. The Cumulative incidences for the primary outcome measure (A), for all-cause death (B), for HF hospitalization (C), and for a composite of all-cause death or all-cause hospitalization (D) according to the presence or absence of functional decline.

Supplementary Online Content

eTable 1. Number of missing values in in the entire cohort

eTable 2. Clinical factors associated with functional decline or in-hospital mortality in the univariate and multivariable analyses in a total of 4056 patients

eFigure 1. The details of functional decline during ADHF Hospitalization.

eFigure 2. Subgroup analysis for the association of functional decline with no functional decline on the primary outcome measure.

For peer review only

eTable 1. Number of missing values in the entire cohort

	Entire Cohort (N=3555)	
	Number	Rate (%)
Tests at admission		
BNP or NT-proBNP *	41	1.15
Serum creatinine	5	0.14
eGFR	5	0.14
Blood urea nitrogen	8	0.22
Albumin	100	2.81
Sodium	11	0.31
Potassium	11	0.31
Haemoglobin	6	0.17

* BNP values were reported for 3140 patients in the entire cohort; NT-proBNP values were reported for 633 patients in the entire cohort.

Abbreviation: BNP, brain-type natriuretic peptide; NT-proBNP, N-terminal-proBNP; eGFR, estimated glomerular filtration rate.


eTable 2. Clinical factors associated with functional decline or in-hospital mortality in the univariate and multivariable analyses in a total of 4056 patients

Variables	Unadjusted OR (95% CI)	P Value	Adjusted OR (95% CI)	P Value
Age ≥80 years	2.97 (2.50–3.52)	<0.001	2.32 (1.86–2.89)	<0.001
Women	1.45 (1.25–1.70)	<0.001	1.13 (0.93–1.38)	0.22
BMI ≤22	1.56 (1.32–1.83)	<0.001	1.21 (1.00–1.47)	0.053
Prior HF hospitalization	1.08 (0.92–1.27)	0.36	0.96 (0.79–1.18)	0.72
Acute coronary syndrome	1.56 (1.16–2.11)	0.003	1.76 (1.19–2.60)	0.005
Hypertension	1.00 (0.85–1.20)	0.95	0.96 (0.77–1.21)	0.75
Diabetes mellitus	0.86 (0.73–1.01)	0.06	0.88 (0.72–1.09)	0.25
Atrial fibrillation or flutter	0.97 (0.83–1.13)	0.67	0.99 (0.81–1.21)	0.90
Prior myocardial infarction	0.94 (0.78–1.13)	0.50	0.89 (0.71–1.13)	0.36
Prior stroke	1.73 (1.43–2.10)	<0.001	1.57 (1.24–1.99)	<0.001
Chronic lung disease	1.11 (0.89–1.39)	0.37	1.16 (0.88–1.52)	0.29
Dementia	2.91 (2.44–3.47)	<0.001	2.24 (1.78–2.82)	<0.001
Current smoking	0.37 (0.27–0.51)	<0.001	0.55 (0.38–0.81)	0.002
Living alone	1.05 (0.87–1.27)	0.62	1.14 (0.91–1.44)	0.26
Ambulatory before admission	0.64 (0.54–0.77)	<0.001	1.44 (1.13–1.84)	0.003
Systolic BP <90 mmHg	2.01 (1.37–2.96)	<0.001	1.17 (0.66–2.05)	0.59
Heart rate <60 beat/min	1.07 (0.79–0.79)	0.66	1.03 (0.71–1.49)	0.88
Body temperature ≥37.5 °C	2.26 (1.72–2.7)	<0.001	1.89 (1.35–2.63)	<0.001
NYHA class III or IV	2.17 (1.62–2.91)	<0.001	1.73 (1.24–2.41)	0.001
LVEF <40%	1.04 (0.89–1.22)	0.61	1.24 (1.00–1.52)	0.047
Anaemia*	1.67 (1.39–1.98)	<0.001	1.08 (0.86–1.36)	0.51
Albumin <3.0 g/dL	2.30 (1.89–2.81)	<0.001	1.91 (1.50–2.43)	<0.001
Sodium <135 mEq/L	1.89 (1.53–2.33)	<0.001	1.72 (1.34–2.22)	<0.001
eGFR <30 ml/min/1.73m ²	2.01 (1.70–2.36)	<0.001	1.78 (1.45–2.19)	<0.001


*Defined by the World Health Organization criteria (haemoglobin <12 g/dL for women and <13 g/dL for men).

Abbreviations: OR, odds ratio; CI, confidence interval; BMI, body mass index; HF, heart failure; BP, blood pressure; NYHA, New York Heart Association; LVEF, left ventricular ejection; eGFR, estimated glomerular filtration rate;.

eFigure 1. The details of functional decline during ADHF hospitalization. Functional status at discharge according to functional status before admission is shown. ADHF, acute decompensated heart failure.



eFigure 2. Subgroup analysis for the association of functional decline with no functional decline on the primary outcome measure. LVEF, left ventricular ejection fraction; HR, hazard ratio; CI, confidence interval.



STROBE 2007 (v4) Statement—Checklist of items that should be included in reports of *cohort studies*

Section/Topic	Item #	Recommendation	Reported on page #
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	Page 1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	Page 3-4
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	Page 6
Objectives	3	State specific objectives, including any prespecified hypotheses	Page 8
Methods			
Study design	4	Present key elements of study design early in the paper	Page 7
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	Page 7-8
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	Page 8
		(b) For matched studies, give matching criteria and number of exposed and unexposed	
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	Page 8-10
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	Page 8
Bias	9	Describe any efforts to address potential sources of bias	Page 10
Study size	10	Explain how the study size was arrived at	Page 8
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	Page 9
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	Page 9-10
		(b) Describe any methods used to examine subgroups and interactions	Page 10-11
		(c) Explain how missing data were addressed	Page 9
		(d) If applicable, explain how loss to follow-up was addressed	Page
		(e) Describe any sensitivity analyses	Page 11
Results			

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	Page 12
		(b) Give reasons for non-participation at each stage	Page 8
		(c) Consider use of a flow diagram	Page 7-8
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	Page 12
		(b) Indicate number of participants with missing data for each variable of interest	Page 7-8
		(c) Summarise follow-up time (eg, average and total amount)	Page 12
Outcome data	15*	Report numbers of outcome events or summary measures over time	Page 14
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	Page 13-15
		(b) Report category boundaries when continuous variables were categorized	Page 10-11
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	Page 14-15
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	Page 15-16
Discussion			
Key results	18	Summarise key results with reference to study objectives	Page 16
Limitations			
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	Page 19-20
Generalisability	21	Discuss the generalisability (external validity) of the study results	Page 19-20
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	Page 22

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.